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Aim of the thesis
The n- versus u-serration is a learnable criterion to differentiate 
pemphigoid from epidermolysis bullosa acquisita in direct immuno-
fluorescence serration pattern analysis
Low sensitivity of type VII collagen ELISA in epidermolysis bullosa 
acquisita: serration pattern analysis on skin biopsy is required for 
diagnosis
IF serration pattern analysis as a diagnostic criterion in  
anti-laminin-332 mucous membrane pemphigoid - immunopatho-
logical findings and clinical experience in 10 Dutch patients-
Bullous pemphigoid as pruritus in the elderly; a common  
presentation
Whole body application of a potent topical corticosteroid for bullous 
pemphigoid







AIBD  autoimmune blistering diseases 
anti-LN-332 MMP  anti-laminin-332 mucous membrane pemphigoid 
BMZ  epidermal basement membrane zone  
BP  bullous pemphigoid
Coll VII  type VII collagen
CS  corticosteroids
DIF  direct immunofluorescence microscopy
EBA  epidermolysis bullosa acquisita
ELISA  enzyme linked immunosorbent assay
FOAM  fluorescent overlay antigen mapping 
G6PD  glucose-6-phosphate dehydrogenase 
GFHD  G.F.H. Diercks, MD, PhD
HDs  hemidesmosomes
IIF  indirect immunofluorescence microscopy
Inf  inflammatory phenotype
IP  immunoprecipitation
KO  knock-out immunofluorescence analysis
LAD  linear IgA bullous dermatosis
LN-332  laminin α3β3γ2
LPP  lichen planus pemphigoides
MB  classic mechanobullous phenotype
MFJ  M.F. Jonkman, MD, PhD
MMP  mucous membrane pemphigoid
MO  monkey esophagus
MTX  methotrexate
NC1  non-collagenous amino-terminal globular domain
NC2  34-kDa, non-collagenous carboxy-terminal globular
NCHA  the Netherlands Consortium for Healthy Ageing
OCP  ocular cicatricial pemphigoid
PG  pemphigoid gestationis
sAIBD  subepidermal autoimmune blistering diseases
SSS  salt split skin analysis
TPMT  thiopurine methyltransferase activity
180-kD antigen  BP180, BPAG2, type XVII collagen
230-kD antigen  BP230, BPAG1
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Pemphigoid is a group of subepidermal autoimmune blistering diseases (sAIBD) which comprise 
many subtypes with a clinical heterogenous appearance, a specific laboratory diagnosis and 
tailor made treatment. This thesis focuses on the clinical symptoms, diagnosis and treatment 
in pemphigoid diseases, especially bullous pemphigoid (BP), mucous membrane pemphigoid 
(MMP), anti-laminin-332 MMP (anti-LN-332 MMP) and epidermolysis bullosa acquisita (EBA)
Epidemiology
Pemphigoid diseases show a rising incidence in the past decades. In Europe the incidence of BP 
is between 13.4-21.7 per one million people.1-4 In the UK, Germany and France the incidence 
of BP has increased substantially (two to five times). This rising incidence may be due to the 
increasing age of the general population and the use of multiple drugs in elderly. Furthermore 
more sensitive and specific diagnostic assays are developed.5 BP occurs preferentially in elderly 
with median age of 80 years old and is known to have significantly associated increased 
mortality rates compared to the general population.4 Cortes et al. reported a 1-year probability 
of death of 20.9% in BP. The mortality rate was three times higher in the BP cohort compared to 
the general Swiss population.6 Associated neurological disorders and patients’ general condition 
are both risk factors and major prognostic factors for BP patients.7 Specific associations are re-
ported between BP and Parkinson’s disease, dementia, stroke, and multiple sclerosis.8 The iden-
tification and characterization of genes and pathways that contribute to the presence or absence 
of BP and neurological diseases is one of the themes to be studied. The Netherlands Consortium 
for Healthy Ageing (NCHA) is an alliance between the Groningen University Medical Centre, 
the Leiden University Medical Centre, the Erasmus Medical Centre, the Academic Medical 
Centre, the VU University and business partners Unilever, Philips, Galápagos, McRoberts, Pfizer 
and DSM. The NCHA integrates scientific disciplines, technological innovations and biomedical 
research in the largest collection of world-renowned human cohort studies. Pemphigoid diseases, 
especially BP, is because of the association with age and neurological disease a disease of elderly 
with many comorbidities. The NCHA can be of use to learn from patient’s genetics and meta-
bolic constitution, life style and the interaction with environmental factors like socio-economic 
status, and use of multiple drugs to identify the factors who contribute to the rising incidence of 
pemphigoid diseases. 




Pemphigoid comprises different subtypes like BP, MMP, ocular cicatricial pemphigoid (OCP), 
anti-LN-332 MMP, anti-p200 pemphigoid, anti-plectin pemphigoid, linear IgA bullous derma-
tosis (LAD), pemphigoid gestationis (PG), lichen planus pemphigoides (LPP), Brunsting-Perry 
pemphigoid and epidermolysis bullosa acquisita (EBA).5,9 The clinical appearance of patients with 
pemphigoid diseases is various, although some subtypes have specific clinical symptoms (Table 
1).
BP is the most common form of pemphigoid. Pruritus, urticaria and tense blisters are the three 
clinical pillars stated in the “Definitions and outcome measures for bullous pemphigoid”.10 The 
predilection sites are the flexor surfaces of the arms and legs, axillae, groin, flanks and abdomen 
(Fig 1-A). Oral lesions are seen in a minority of patients and the lesions are usually transient. 
BP may start with pruritus in the prodromal stage, while blisters develop weeks or months later. 
Confusing is the subset of patients with immunopathological findings of BP, pruritus, but no 
blister development for years (Fig 1-B). In a Swiss study 20% of 160 diagnosed BP patients 
presented without blisters.11 In the literature there is no consensus on how to name this subset 
of patients. The coined terms include ‘pruritic pemphigoid’, ‘pemphigoid nodularis’, ‘papular 
pemphigoid’, ‘prurigo-nodularis like pemphigoid’, ‘non-bullous BP’, ‘prodromal BP’, ‘cutaneous 
pemphigoid’ and ‘BP incipiens’.12-19 It is important to be aware of this subtype of pemphigoid 
because these patients, mainly elderly, presenting with pruritus sine materia (no skin lesions) or 
wit non-bullous skin lesions are frequently misdiagnosed as xerosis, drug reaction, dermatitis, 
renal impairment, liver impairment or scabies.
MMP predominantly affects different types of mucosa and sometimes the skin.20 Compared to 
BP, clinical symptoms appear earlier in life (mean age 60-65 years). The oral cavity (85%) is the 
most common site involved, followed by ocular disease (65%). The nasal (20-40%), pharyn-
geal (20%), laryngeal (5-10%), anogenital (20%) and esophagus (5-15%) region can also be 
affected.9,20,21 All sites involved tend to heal with scar formation, although in the oral cavity 
re-epithelisation without scarring can occur. OCP is a subtype of MMP in which the eyes are 
the only affected mucosa, causing progressive cicatrization. OCP usually starts unilaterally with 
clinical features of dry eye, conjunctivitis, trichiasis, symblepharon formation and finally resulting 




In patients with anti-LN-332 MMP, airway obstruction due to pharyngeal and laryngeal involve-
ment is a serious complication and is seen more often than in other forms of MMP.23 In the first 
instance patients present with aphonia (loss of voice) due to oedema, erosions and ulcerations 
of the supraglottic area. This is followed by scarring of the larynx, and acute upper airway 
obstruction due to initial laryngeal oedema may occur, necessitating tracheotomy.24,25 The nose, 
esophagus and anogenital region are other frequent affected mucosal surfaces.26 Patients with 
anti-LN-332 MMP have an increased relative risk for malignancy and should be thoroughly 
screened. Adenocarcinoma like lung cancer and stomach cancer were found mostly.27-29 
Anti-p200 pemphigoid is a rare disease and clinical heterogenous. Patients present with tense 
blisters and urticaria, mimicking BP. Generally the disease starts at a younger age compared to 
BP. Till now, the classical clinical presentation and pathogenic autoantibodies in this disease is not 
clarified.30,31
Clinically EBA can present at any age with either the classic mechanobullous (MB) phenotype 
or as the inflammatory (Inf) phenotype that mimicks other pemphigoid diseases as BP, MMP or 
LAD.32 The classical MB phenotype mimics dystrophic epidermolysis bullosa hereditaria and is a 
non-inflammatory mechanobullous disease primarily involving trauma-prone areas of skin, such 
as the hands, elbows, knees, and feet. These lesions heal with scarring resulting in milia. Inf EBA 
is clinical heterogenous with a widespread of non-scarring vesiculobullous eruption that mainly 
involves the intertriginous region and flexures, and in some cases the oral mucosa. Different 
subtypes may occur like: Inf-BP like, Inf-MMP like or Inf-vesicular pemphigoid like. Buijsrogge 
et al. described the many faces of EBA and concluded that 2/3 of the EBA patients show the 
Inf phenotype.33 IgA EBA presents with intense pruritic widespread or localized vesicles with 
frequently involvement of mucosal surfaces without cicatrization.








Bullous pemphigoid BP180 
BP230
Pruritus, urticaria, tense blisters, 
eczema, papules or nodules without 
predominant mucosal involvement
Potent topical CS, systemic CS. Antibiotics, 
nicotinamide, azathioprine, mycophenolate 






Erosions and blisters of the oral, 
nasal, eyes, pharyngeal, laryngeal, 
esophagus and anogenital mucosa
Low risk: Potent topical CS, antibiotics, 
dapsone  
High risk: systemic CS, dapsone, cyclo-





LN-332 Erosions and ulcerations of the 
supraglottic area, nose, eyes, 
esophagus and anogenital region, 
aphonia, dyspnoe
Systemic CS, dapsone, cyclophosphamide, 




BP180 Dry eyes, conjunctivitis, trichiasis, 
symblepharon, blindness  
(Tauber classification system)
Systemic CS, dapsone, cyclophosphamide, 
azathioprine, mycophenolate mofetil, 
mycophenolic acid




Tense blisters and erosions (“crown 
of jewels” and “string of pearls”). 
Oral, nasal and genital erosions and 
crustae (70%)







Blisters and erosions of the trau-
ma-prone areas of the skin, healing 
with milia and scarring
Systemic CS, colchicine, azathioprine, my-






bullous eruption, without predomi-
nant mucosal involvement
Potent topical CS, systemic CS.  
Antibiotics, nicotinamide, azathioprine, 
mycophenolate mofetil, mycophenolic 
acid, methotrexate, dapsone
Pemphigoid gestationis BP180 Intense pruritic urticarial rash, 
papules and tense blisters starting 
around umbilicus and then spread 
over the body





Erosions and blisters limited to the 
head, face, neck and upper trunk 
leaving atrophic scars
Potent topical CS or systemic CS. 
Azathioprine, mycophenolate mofetil, 
mycophenolic acid





Tense blisters independent of the 
lichenoid plaques and papules of 
lichen planus
Treatment of lichen planus and treatment 
algorithm for bullous pemphigoid
Table 1: Target antigens, clinical symptoms and treatment of pemphigoid diseases. CS: corticosteroids; MB phenotype: 
mechanobullous phenotype; Inf phenotype: inflammatory phenotype
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Figure 2: Overview of the epidermal basement membrane zone. The proteins that are targeted by autoantibodies in  
pemphigoid diseases are colored in red.
Figure 1: Clinical and immunopathological features of bullous pemphigoid. Tense blisters and erosions on the left arm (A); 
Excoriated papules and nodules on both legs (B); Direct immunofluorescence microscopy perilesional showing deposits of 
IgG in the n-serrated pattern (C); Indirect immunofluorescence microscopy on salt split skin analysis showing epidermal 
binding of the blister (D)
Target Antigens 
Pemphigoid is characterized by subepidermal cleavage of the skin due to circulating autoan-
tibodies targeting antigens in the epidermal basement membrane zone (BMZ) (Fig 2).9 The 
basal keratinocytes in the skin are attached to their underlying BMZ via specialized adhesion 
complexes termed hemidesmosomes (HDs). HDs are multiprotein complexes and contribute 
to the stability of stratified epithelia of the skin, gastro-intestinal and respiratory tract. Defects 
in components of these adhesion complexes often result in tissue fragility and blistering of the 
skin.34-36 
The 180-kD antigen (BP180, BPAG2, or type XVII collagen), and the 230-kD antigen (BP230, 
BPAG1) are the main target antigens in BP, MMP, LAD, PG, OCP, Brunsting-Perry pemphigoid 
and LPP.5,9 BP180 is a 180-kDa transmembrane glycoprotein that ultrastructurally spans the 
lamina lucida and curves back from the lamina densa into the lamina lucida.37-39 The non-collag-
enous NC16A ectodomain of BP180 is the immunodominant region in BP.40 BP230 is a cyto-
plasmic protein involved in the anchorage of intermediate filaments (IF) to the cytoskeleton.37,41 
Anti-LN-332 MMP is a form of pemphigoid with circulating autoantibodies targeting LN-332. 
This is a heterotrimeric protein consisting of α3, β3 and γ2 subunits (laminin α3β3γ2). LN-332 
is present in the basal lamina of various epithelia including stratified squamous epithelium, and 
connects hemidesmosomes to anchoring fibrils by interlinking integrin alpha6beta4 and BP180 
to type VII collagen.42-45 The 290-kDa antigen (type VII collagen, C7), the major structural 
component of the anchoring fibrils located in the BMZ, is the targeted antigen in EBA.46,47 The 
molecule itself is a trimer consisting of three identical alpha-chains. Each chain contains a 145-
kDa central collagenous triple-helical region, that is flanked by a large 145-kDa, non-collagenous 
amino-terminal globular domain (NC1) and a smaller, 34-kDa, non-collagenous carboxy-ter-
minal globular domain (NC2). Within the extracellular space these molecules form anti-parallel 
tail to tail dimers which then conglomerate on the lateral side to form anchoring fibrils.48,49 The 
immunodominant epitopes of C7 are particularly located within the NC1 domain and in the 
minority in the NC2 domain or central collagenous domain.50-52
Anti-p200 pemphigoid  is characterized by circulating autoantibodies against the 200-kDa-pro-
tein of the lower lamina lucida. Dainichi et al. described that the 200-kDa-protein corresponded 
in the majority of their patients (90%) with the C-terminus of laminin gamma 1, an extracellular 
matrix glycoprotein composing several forms of laminin heterotrimers, and named the disease 
anti-laminin γ1 pemphigoid.30 However, the pathogenic relevance of these autoantibodies has 




Diagnosis in patients clinically suspected for pemphigoid diseases is based on a combination of 
clinical features, histopathological examination, detection of in vivo bound autoantibodies (IgG, 
IgA, IgM, C3c and fibrin) in skin or mucosa (DIF), and detection of antigen specific circulating 
autoantibodies in the serum (IIF).
The most important use of a skin biopsy for histopathology is to determine the level of split in 
the skin. Intra-epidermal split is associated with pemphigus and subepidermal split is associated 
with pemphigoid. The type of infiltrate seen in the biopsie may be a clue for the diagnosis, but 
no infiltrate is specific for a subtype of pemphigoid. Because multiple diseases are associated 
with intra- or subepidermal split, immunofluorescence microscopy is mandatory to diagnose 
pemphigoid.
DIF allows us to demonstrate linear depositions of immunoreactans in the BMZ. These linear 
depositions of IgG or IgA can have two distinct serration patterns: the n-serration, and the 
u-serration pattern.53 Recognition of DIF serration patterns must be standardized for optimal 
determination: i) perilesional biopsies of non-scarring skin not exposed to topical corticosteroids, 
ii) transporting biopsies without freezing in saline for 24 hours, iii) thin cryosections 
(4 µm thickness or less), iv) lens objective of at least 40x and appropriate microscope filters. 
The u-serration pattern confirms the diagnosis EBA, and represents immunoglobulin deposi-
tions in upstanding arms (“grass”) of the sublamina densa zone between the rootlets of basal 
keratinocytes. In all other forms of pemphigoid the antigens are located in the lamina lucida or 
above, so the immunodepositions follow the rootlets of the basal keratinocytes showing the 
n-serration pattern (Fig 1-C).5,53 In few cases the serration pattern is undeterminable. This can be 
due because the serration pattern can not always be recognized, especially in mucosal biopsies. 
In patients with OCP, DIF (conjunctiva) is frequently the only positive assay. These biopsies can 
be performed by the dermatologist or ophthalmologist. DIF serration pattern analysis has found 
limited use nowadays, although the criterion is mentioned in textbooks,54 and in the forthcoming 
European guideline on BP. The limited use might be caused by uncertainty and lack of training 
of the IF microscopists. In our Centre for Blistering Diseases in Groningen, the Netherlands, DIF 
serration pattern analysis is routinely used. With the use of this assay we are able to make in 
almost any case suspected for pemphigoid a final diagnosis when DIF is positive. DIF serration 
pattern analysis can also be used as a diagnostic criterion in EBA. The current criteria to diagnose 
EBA consists of: (i) acquired bullous disease within the defined clinical spectrum, (ii) histologically 
subepidermal cleavage, (iii) DIF of perilesional skin revealing linear IgG along the BMZ, (IV) 
positive alternative laboratory test like IF on salt split skin analysis (SSS), IIF using substrate 
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deficient in BMZ molecules, Western blotting, Fluorescent Overlay Antigen Mapping (FOAM), 
and ELISA.55 When the criterion DIF of perilesional skin revealing linear IgG along the BMZ is 
used alone, no difference can be made between EBA and other forms of pemphigoid. Especially 
with the knowledge that in about 50% of the EBA patients no circulating autoantibodies in the 
serum can be detected. In these cases u-serration pattern by DIF is decisive. 
Another subtype of pemphigoid, anti-LN-332 MMP, is diagnosed on the following criteria 
described previously: (i) chronic subepithelial blistering lesions of mucous membranes and skin, 
(ii) DIF microscopy showing linear deposits of IgG with or without C3c along the BMZ, (iii) 
IIF microscopy showing IgG autoantibodies binding to the dermal side salt-split human skin, 
and (iv) circulating IgG anti-BMZ autoantibodies that immunoprecipate LN-332 from human 
keratinocyte extracts.26,56,57 Anti-p200 pemphigoid, EBA and anti-LN-332 MMP all show IgG 
autoantibodies binding to the dermal side salt-split human skin.
Serological analysis for circulating autoantibodies is of great use in the diagnostic approach. 
Traditionally IF is performed on frozen sections of standard substrates like monkey esophagus, 
human split-skin and rat bladder.58 Serum samples from patients with MMP are serological 
positive in a low percentage (50-80%) and when positive it is in low titres. Circulating IgA 
autoantibodies can be detected in the majority of the MMP patients (60%). When IgG and IgA 
autoantibodies are both present, patients have a more severe and persistent MMP compared to 
patients with only IgG autoantibodies.59,60
SSS is useful to differentiate between different groups of autoantigens. Incubation of human 
skin in 1.0 M NaCl leads to a reproducible split through the lamina lucida.The hemidesmosomes 
associated antigens 180-kDa, 230-kDa, plectin, integrin alpha6beta4 and LAD-1 are located 
in the epidermal side of the blister (Fig 1-D), and the antigens LN-332, p200 and 290-kDa are 
located at the dermal side of the blister.61-64 The combination of serration pattern analysis by DIF 
and SSS is for the clinician in many cases already decisive. These assays should be available in 
any routine diagnostic laboratory. 
In specialized laboratory and in Blistering Centres additional tests like immunoblot,  
enzyme-linked immunosorbent assay (ELISA), immunoprecipitation (IP) , knock-out immuno- 
fluorescence analysis (KO) and FOAM are available. 
Immunblot (also called Western blot) is an analytical technique that allows to demonstrate spe-
cific protein expression. Proteins to be analyzed are resolved by electrophoretic separation over 
a polyacrylamide slab-gel in the presence of sodium dodecyl sulphate (SDS-PAGE) and brought 
on a membrane. The interaction between the membrane and patients’ serum makes the antigen 
visible which is targeted by IgG. The advantage of this assay is the possibility to test multiple 
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antigens in one immunblot. On the other hand conformational epitopes can be destroyed by the 
denaturation process whereby the IgG binding to the membrane is not feasible.65
ELISA is a diagnostic criterion to detect the presence and the titer of specific autoantibodies in 
the serum of a patient. A specific antigen is coated onto a plastic well and the well is incubated 
with patients’ serum. When IgG to this antigen is present, it will bind the immobilized antigen. 
Then after washing the well, the amount of IgG is visualized by colorimetric reaction. The  
intensity of the color is a measure of the amount of autoantibodies in the blood of the patient. 
In contrast to immunblot, ELISA is a quantitative assay and can be used as a tool to monitor 
disease activity in different subtypes of pemphigoid.66-68
Recently new ELISA’s for the detection of autoantibodies against C7 have been developed 
that has the recombinant NC1 and NC2 coll VII domains coated to the plate. A high sensitivity 
(>93%) and specificity (>96%) has been reported.68,69 However all these studies relied on sera 
that were positive by SSS analysis. 
IP is used to precipitate antigens out of an extract using patient autoantibodies immobilized on 
a solid support, such as agarose or magnetic beads. IP can in contrast to immunoblot detect 
conformational epitopes. IP is not general used as it requires radiolabeled protein extracts and 
therefore specially equipped laboratories.
KO is an assay which allows to differentiate between anti-LN-332 MMP and EBA patients. The 
serum of the patient will be brought on a section of C7-deficient skin from a patient with severe 
recessive dystrophic epidermolysis bullosa, and on a section of LN-332 deficient skin of a patient 
with Herlitz-type junctional epidermolysis bullosa. When the serum does not bind to C7 deficient 
skin, but will bind to LN-332 deficient skin, this confirms the presence of anti-C7 autoantibod-
ies.70
FOAM is a specialized technique developed in our laboratory and makes it possible to distinguish 
between deposits above (BP, anti-LN-332 MMP) and below (EBA) the lamina densa. By double 
staining the deposited IgG and the antigen overlap or non-overlap can be visualized.71 FOAM 
can be very useful as a diagnostic criterion in cases in which DIF, IIF, immunblot and ELISA are 
not conclusive.
With all these tests available in different laboratories, clinicians must be able to solve the most 
complicated diagnostic cases of pemphigoid. By combination of these tests in Centres for 
Blistering Diseases, the knowledge in the diagnostic approach in pemphigoid diseases will be 
centralized, and more accurate diagnoses can be made.




Treatment of pemphigoid is challenging because of the variable age of the patients, differences 
in disease severity, progressive scarring of mucosa and the presence of comorbidities (Table 1). 
The aim of the therapy is to induce healing of the lesions on the skin and/or mucous membranes 
and to minimize adverse effects of the treatment as much as possible. 
Topical and systemic corticosteroids (CS) are first line therapy in patients with pemphigoid. 
Topical CS should be considered in any patient with BP.72 The French “Group Bulle” showed the 
efficacy of topical clobetasol propionate cream (10-30g) application on the whole body, progres-
sively tapered over 4 months in moderate BP.73 The same group also examined  the effectiveness 
of topical clobetasol propionate cream compared to treatment with oral CS in patients with BP, 
showing that topical CS is effective and increased survival for both moderate and severe BP and 
is superior to systemic CS for extensive disease.74 It is likely that the high efficacy of whole body 
topical clobetasol propionate application is due to both local and systemic effects. Van Velsen 
et al. have showed the systemic absorption and effects of whole body application of clobetasol 
propionate 0.05% cream in patients with atopic dermatitis.75 Systemic absorption of clobetasol 
propionate 0.05% cream has never been described before in BP patients. 
According to current evidence systemic CS is the best established treatment.76 The dose of sys-
temic CS given is 0.5-0.75 mg/kg/day. When after four weeks lesions tense to heal or stabilize, 
treatment can be judged as successful and tapering of dose should be started. Dose above 
0.75 mg/kg/day is not more effective and is associated with higher mortality and increased 
adverse effects.76 During treatment with systemic CS one should be aware of potential risks such 
as hypertension, osteoporosis, hyperlipidemia, diabetes mellitus, psychiatric disorders, cataract, 
glaucoma, and systemic infections which can be life threatening.76 Gastric protection and 
osteophorosis prophylaxis must be prescribed.
Adding a CS sparing adjuvant is important to reduce the adverse effects caused by longterm 
CS use. In BP one can choose for antibiotics (tetracycline, doxycycline, minocycline) with or 
without nicotinamide (up to 1500 mg), azathioprine (2-3mg/kg/day), mycophenolate mofetil 
(2g/day), mycophenolic acid (720 mg twice/day), methotrexate (10-20 mg/week) or dapsone 
(100-200mg/day). Before introducing a CS sparing adjuvans routine blood screening and 
specific serological assays like thiopurine methyltransferase (TPMT) activity (azathioprine) and 
glucose-6-phosphate dehydrogenase (G6PD) deficiency (dapsone) must be performed. The 
use of rituximab (anti-CD20 monoclonal antibody), high-dose intravenous immunoglobulin, 
plasmapheresis or immunadsorption is described in refractory patients.77-80 
As stated before treatment of patients with MMP is challenging because of the scarring potential 
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of certain mucous membranes like ocular and laryngeal mucosa. Patients can be divided in i) 
low risk MMP (affection oral mucosa with or without skin lesions), ii) high risk MMP (affection 
of any other mucosa). Low risk MMP can be treated with topical potent CS with or without an-
tibiotics or dapsone. High risk MMP is treated more aggressively with systemic CS and dapsone 
(100-200mg/day), cyclophosphamide (100-200mg/day), mycophenolate mofetil (2g/day) or 
mycophenolic acid (720 mg twice/day). Dexamethasone pulse therapy or systemic CS (1.0mg/
kg/day) in combination with cyclophoshamide should be first choice of treatment in rapidly 
progressive OCP or anti-LN-332 MMP patients with impending blindness or airway obstruction 
due to pharyngeal and laryngeal involvement. Rituximab (anti-CD20 monoclonal antibody) 
and high-dose intravenous immunoglobulin are both used with good results in refractory MMP 
patients.81,82
EBA, classical MB phenotype, is known to be therapeutic refractory. Treatment with oral CS 
(0.5-1.0 mg/kg/day) is used in first instance and steroid sparing adjuvant is introduced simul-
taneously. The use of colchicine is described to be successfull, although the adverse effects of 
gastro-intestinal complaints can make it difficult for patients to achieve the prescribed dosage.32 
In our clinic we use azathioprine (2-3mg/kg/day), dapsone (100-200 mg/day), mycophenolate 
mofetil (2g/day) or mycophenolic acid (720 mg twice/day). Rituximab (anti-CD20 monoclonal 
antibody) and high-dose intravenous immunoglobulin are described to reduce symptoms in 
refractory EBA patients.83-85 Inf EBA can be treated similar to BP. Dapsone is first choice of 
treatment in IgA EBA patients.
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Aim of the thesis 
The Centre for Blistering Diseases, Department of Dermatology, University of Groningen, 
University Medical Centre Groningen, Groningen, the Netherlands, is the national referral centre 
were patients with pemphigus and pemphigoid from the Netherlands and foreign countries are 
seen. The combination of high quality laboratory diagnostics and high standard clinical practice 
provides this centre to be leading in the field of autoimmune blistering diseases. The aim of this 
thesis is to provide more insight for the clinician in clinical symptoms, diagnosis and treatment 
in pemphigoid diseases, especially bullous pemphigoid (BP), mucous membrane pemphigoid 
(MMP), anti-laminin-332 MMP (anti-LN-332 MMP) and epidermolysis bullosa acquisita (EBA).
To spread our knowledge of the serration pattern analysis and to encourage dermatologists 
and pathologists to use this assay in daily practice we developed in chapter 2 an image-based 
online test and instruction video to test the learnability of n- and u-serrated DIF patterns before 
and after instruction. The purpose of this test is to demonstrate the importance of the serration 
pattern analysis as a diagnostic criterion in pemphigoid diseases and to show that adequate 
interpretation is learnable. For that reason our online nversusu-test is worldwide online available 
and free of charge.
In chapter 3 we investigated the possible use of a new C7 ELISA for initial diagnosis of EBA. 
Furthermore we tested if C7 ELISA is a possible tool for monotoring disease activity, since 
this would provide the dermatologist with an assay to investigate the effect of medication on 
antibody levels.
Anti-LN-332 MMP is a rare disease and in chapter 4 we focus on the immunopathological 
findings, clinical features and describe the therapeutic management in 10 patients with 
anti-LN-332 MMP to enhance the knowledge of this subtype of MMP and to describe the 
clinical differences compared to anti-p200 pemphigoid, which shows similarity in DIF serration 
pattern analysis (n-serrated pattern) and SSS (dermal binding). 
In chapter 5 we describe 15 patients selected over the period 2002-2012 from the biobank of 
our Centre for Blistering Diseases with immunopathological findings of BP, intense pruritus, and 
no development of blisters and define clinical features and treatment of this group of patients. 
In chapter 6 we investigate the efficacy and adverse effects of whole body topical clobetasol 
propionate cream application in patients with mild or severe BP and we also focus on the 
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Background Serration pattern analysis of direct immunofluorescence (DIF) allows differentiating 
epidermolysis bullosa acquisita (EBA) from other subtypes of pemphigoid. In daily practice its use 
is limited due to lack of experience and unfamiliarity.
Objectives To test the learnability of DIF serrated pattern recognition under groups with various 
a priori levels of competence.
Methods An online nversusu-test (www.nversusu.umcg.nl) was created, which contained 26 
DIF images of the epidermal basement membrane zone (BMZ), IgG stained, and photographed 
with a magnification of 40x and 63x. All images represented patients with a form of subepider-
mal autoimmune bullous disease. Thirteen DIF images were presented before and thirteen DIF 
images after an instruction video about n- and u-serrated patterns. There were three options to 
choose from: n-serrated, u-serrated or undetermined. The test was completed by three groups 
of professionals: i) dermatology residents in training at the University Medical Centre Groningen, 
ii) International experts on bullous diseases, iii) dermatologists and pathologists who participated 
in the Groningen Blistering Course in the last 10 years. 
Results Overall the number of correct answers of serration patterns was significantly higher 
after instruction than before instruction (median 9.0 correct answers vs. 11.0 correct answers, 
P<.001). Participants showed a mean improvement after instruction of 15.4% in the UMCG 
group (66.7% vs. 82.1%), 16.2% in the International expert group (67.2% vs. 83.4%) and 
12.1% in the Blistering Course group (60.7% vs. 72.8%). The u-serrated pattern was better 
recognized than the n-serrated.
Conclusion Serration pattern analysis by DIF can be learned irrespective of background of 
expertise.
Introduction
Acquired subepidermal autoimmune blistering diseases (sAIBD) comprises bullous pemphigoid 
(BP), mucous membrane pemphigoid (MMP), anti-laminin-332 MMP (anti-LN-332 MMP),  
anti-p200 pemphigoid, anti-plectin pemphigoid, linear IgA bullous dermatosis (LAD), pemphi-
goid gestationis (PG), lichen planus pemphigoides (LPP), and epidermolysis bullosa acquisita 
(EBA). Each subtype is characterized by circulating autoantibodies targeting components of the 
epidermal basement membrane zone (BMZ).1 The main target antigens in BP, MMP, LAD, PG 
and LPP are the 180-kD antigen (BP180, BPAG2, or type XVII collagen), and the 230-kD antigen 
(BP230, BPAG1). These are components of the hemidesmosomal plaque, adhesion structures 
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that anchor the basal cells to the underlying BMZ.1 Anti-LN-332 MMP shows circulating autoan-
tibodies targeting LN-332 which connects hemidesmosomes to anchoring fibrils by interlinking 
integrin alpha6betha4 to type VII collagen.2 EBA shows autoreactivity to the 290-kDa antigen 
(type VII collagen), the major structural component of the anchoring fibrils located in the BMZ.3  
In 2004, Vodegel et al. described the serration pattern analysis by routine direct immunofluores-
cence (DIF) showing linear n-serration or linear u-serration immunodepositions along the BMZ.4 
The u-serration pattern confirms the diagnosis EBA, and represents immunoglobulin depositions 
in upstanding arms (“grass”) of the sublamina densa zone between the rootlets of basal 
keratinocytes.3 In all other sAIBDs the antigens are located in the lamina lucida or above, so the 
immunodeposits follow the rootlets of the basal keratinocytes showing the n-serration pattern.2,4
However since its first publication, DIF serration pattern analysis has found limited use, although 
the criterion is mentioned in textbooks5, and in the forthcoming European guideline on AIBD. 
The limited use might be caused by uncertainty and lack of training of the IF microscopists. 
Aim of this study is to test the learnability of n- and u-serrated DIF patterns before and after 
instruction. Moreover, for knowledge transfer, our image-based online test and instruction video 
is available online free of charge. To display the importance of DIF serration pattern analysis as a 
diagnostic criterion in subtyping sAIBD, we first present two cases in which it had an important 
role in early diagnosis.
Report of cases
A 42-year old female presented with desquamative gingivitis with oral ulcerations (Fig 1-AI), 
intra-nasal crustae, symblepharon (Fig 1-AII), and laryngeal involvement without skin symptoms. 
DIF of a skin biopsy showed linear IgG deposition along the BMZ in the n-serrated pattern. 
Indirect immunofluorescence (IIF) of serum on monkey esophagus (MO) showed circulating 
anti-BMZ IgG and IIF on salt-split skin (SSS) revealed IgG binding to the dermal side of the split. 
The combination of mucosal symptoms, n-serrated pattern by DIF, and dermal binding by SSS 
was suggestive for anti-LN- 332 MMP (Fig 1-AIII). Diagnosis was confirmed by a positive ELISA 
against native LN-332 
A 31-year old male presented with urticarial plaques on the trunk (Fig 1-BI), mechanobullous 
blistering on hands and feet, and milia on the dorsal side of the hands (Fig 1-BII). DIF showed 
linear IgG deposition along the BMZ in the u-serrated pattern. IIF on MO showed circulating 
IgG against the BMZ, and IIF on SSS showed IgG binding to the dermal side of the split. The 
combination of clinical symptoms, u-serrated pattern by DIF (Fig 1-BIII) and dermal binding of 
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SSS was suggestive for classic mechanobullous EBA. This diagnosis was confirmed by immuno-
blot demonstrating IgG binding the 290 kDa-antigen and a positive type VII collagen ELISA.
Material and Methods
Study design
An image-based online test (www.nversusu.umcg.nl) was created, using LimeSurvey software.6 
The test included 26 DIF images of the BMZ, all biopsies were IgG stained and photographed 
with a 40x and 63x objective. First, the participant had to score thirteen DIF images, then an 
instruction video about n- and u-serrated pattern recognition was presented, and subsequently 
the participant had to score thirteen other DIF images. The short instruction video contained 
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Figure 1: Clinical features and serration pattern analysis by direct immunofluorescence (DIF) in patient (A) anti-laminin-332 
MMP and patient (B) epidermolysis bullosa acquisita, mechanobullous phenotype. (A-I) desquamative gingivitis, (A-II) con-
junctivitis with symblepharon, (A-III) n-serrated pattern by DIF. (B-I) urticarial plaques on the back, (B-II) milia on the dorsal 
side of the hand, (B-III) u-serrated pattern by DIF.
instructions how to recognize the different serrated patterns with simple mnemonics: undulating 
n or u-serrated grass.4 To reduce guessing and stay close to real practice the participant could 
also score undetermined, besides n-serrated and u-serrated. 
Participants
Three groups of participants were selected who had a different a priori level of expertise on the 
subject: i) dermatology residents from the University Medical Centre Groningen (UMCG), ii) 
International experts in blistering diseases, who were selected by the network of MFJ derived 
from the EADV Task Force on Autoimmune Bullous Diseases and the Pre-International Inves-
tigative Dermatology Symposium on Autoimmune Bullous Diseases in Lübeck, 6-7 May 2013, 
iii) dermatologists and pathologists who had participated in the annual Dutch Blistering Course 
Groningen within the years 2005-2012.
Patients
Tissue samples of patients with sAIBD were collected from the biobank of the Groningen Centre 
for Blistering Diseases in the Netherlands from the period 2002-2012. The 26 patients included 
in this study were selected by previously confirmed positive DIF, showing a linear deposition 
pattern along the BMZ in a serrated pattern. The final diagnosis was based on clinical, routine 
laboratory, histological and immunopathological findings. Tissue samples with the n-serrated 
deposition pattern (n=13) included patients with one of the following diagnoses: bullous  
pemphigoid (BP; n=5), mucous membrane pemphigoid (MMP; n=5), or anti-laminin-332 
mucous membrane pemphigoid (anti-LN-332 MMP; n=3). Tissue samples with the u-serrated 
deposition pattern included patients with epidermolysis bullosa acquisita (EBA; n=10). Three 
tissue samples showed an undetermined serration deposition pattern (BP; n=2 and EBA; n=1).
Direct immunofluorescensce microscopy (DIF)
The 4 mm IF punch biopsies were all derived from perilesional (erythematous) skin and had been 
transported prior to freezing in saline for 24 hours. Cryosections of 4 μm thickness were cut and 
mounted on polysine™ glass slides, air-dried for 30 minutes in front of a fan, and encircled with 
a hydrophobic emulsion pen (PAP pen, DAKO, Glostrup). The sections were then stained for 
30 minutes with Fc-specific fluorescein isothiocyanate (FITC)-conjugated goat anti-human IgG. 
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The sections were examined with a Leica DMRA microscope (Leica, Wetzlar, Germany). Digital 
fluorescence images were acquired using a Leica DFC350FX camera (Leica, Wetzlar, Germany). 
Further image processing was done by Leica Application Suite software. The images of the 
serration pattern were validated until 100% concordance by two experts (GFHD and MFJ) and 
randomly assigned in the test before and after instruction. Participants had the possibility to 
leave their comments after completing the test. 
Statistical analysis
Wilcoxon signed rank test was used to compare the scores of correct answers of serration 
patterns of the total group of participants before and after instruction. Scores of correct answers 
before and after instruction between the three groups of participants were compared using  
Kruskal-Wallis test.  For all tests, two-sided p-values of less than 0.05 were considered to indi-
cate statistical significance. All analyses were performed using commercially available software 
(SPSS, version 20, IBM).
Results 
We sent 200 invitations to participate in the test; eighty-seven participants completed the 
online nversusu-test (Table 1). The UMCG group scored a response rate of 100% (33/33), the 
International experts scored 50% (19/38) response rate and in the Blistering Course participants 
27% (35/128) performed the test.
The mean scores of correct answers before and after instruction of all participants were respec-
tively 64.4% and 78.6% (P<.001). After instruction overall 60 participants (69%) improved in 
score, 10 participants (11.5%) worsened and 17 participants (19.5%) had the same score as 
before instruction. The mean improvement after instruction was 15.4% in the UMCG group 
(66.7% vs. 82.1%), 16.2% in the International expert group (67.2% vs. 83.4%) and 12.1% in 
the Blistering Course group (60.7% vs. 72.8%) (Fig 2). No significant difference in learnability 
was observed between groups.
DIF images with u-serrated patterns were recognized best, with a mean of 75% correct answers, 
whereas the n-serrated pattern was recognized with a mean of 69%. Remarkably, the undeter-
mined patterns were well scored with correct answers in 68%. The best and least recognized DIF 
images of n-serrated, u-serrated and undetermined pattern are shown in figure 3. Participants 
scored 26% “undetermined” before the instruction video, compared to 18% “undetermined” 
after instruction.












No. of correct 
answers1
% No. of correct 
answers1
%
UMCG 33 8.7 ± 2.3 66.7 10.7 ± 1.3 82.1 <.001
Blistering Course 35 7.9 ± 2.2 60.7 9.5 ± 2.2 72.8 <.001
International 
Expert
19 8.7 ± 2.5 67.2 10.8 ± 1.5 83.4 .003
All 87 8.4 ± 2.3 64.4 10.2 ± 1.8 78.6 <.001






































Figure 2: Total scores of the number correct answers of serration pattern analysis by direct immunofluorescence before and 
after instructions in three different groups.
Table 1: Correct answers of serration pattern analysis by direct immunofluorescence of the test before and after instruction. 
Data are means ± SD, * P-value by Wilcoxon signed rank test
Comments of participants
Many participants commented positively on the high quality of the DIF images and serration 
patterns, a very clear instruction video and emphasized this is an easy way of learning about 
DIF serration patterns and encouraged us to make the test available to the public for teaching 
purposes.
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Figure 3: Best and least recognized serration pattern by direct immunofluorescence images: n-serrated (A: 88%; B: 47%), 
u-serrated (C: 96%; D: 40%) and undetermined (E: 88%; F: 44%). IgG stained, 63x magnification.
Discussion
In this study we show that recognition of n- and u serration pattern by DIF is learnable irrespec-
tive of the level of expertise. The overall a priori level of serration pattern recognition was high 
with 69.2%. Significant improvement to 84.6% was reached by the online instruction video. 
No significant difference in a priori knowledge was observed between the three groups, what 
suggests that the International expert group, despite of their experience in sAIBD, is not more 
experienced in serration pattern analysis than the other participants in this study. The number of 
undetermined scores declined after viewing the instruction video, which suggests that partici-
pants are more confident in serration pattern analysis after instruction.
In serological negative cases or in cases in which IIF in combination with immunoblot and/or 
ELISA is not conclusive, serration pattern analysis of direct immunofluorescence (DIF) might 
disclose the diagnosis (Fig 4). Since more than half of the EBA patients do not have detectable 
circulating antibodies by either ELISA or SSS, DIF serration pattern analysis on perilesional skin 
biopsy is mandatory for diagnosis of an AIBD.3,7 Buijsrogge et al. described a frequency of 
5.5% EBA among patients with sAIBD when DIF serration pattern analysis is used.3 We expect 
that many of those with inflammatory EBA are misdiagnosed as having pemphigoid when DIF 
serration pattern analysis is lacking. 
For daily practice, adequate recognition of DIF serration pattern must meet the following 
standards: i) perilesional biopsies of non-scarring skin not exposed to topical corticosteroids, ii) 
transporting biopsies without freezing in saline for 24 hours, iii) cryosections of high quality (4 
µm thickness or less), iv) lens objective of at least 40x.4,8
Limitations of our study are in the first place the possibility of selection bias, since we had a 
response rate of only 42%. Invited participants who were interested in serration pattern analysis 
might respond more often than invited participants with less experience in serration pattern 
analysis. Secondly, although the DIF images were of high quality standard, self assessment of 
the slides under a microscope is superior and might even give better results. Finally, in general 
it is important to realize that the serration pattern not always can be recognized, especially in 
mucosal biopsies.4
In conclusion, we show that serration pattern analysis by DIF is learnable. Our image-based 
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Figure 4: Overview of the serration pattern, IIF on salt split skin (SSS) and sAIBD; n-serrated in BP: bullous pemphigoid, 
MMP: mucous membrane pemphigoid, CP: cicatricial pemphigoid, LAD: linear IgA dermatosis, p200: anti-p200 pemphigoid 
and anti-LN-332: anti-laminin-332 mucous membrane pemphigoid. U-serrated in EBA: epidermolysis bullosa acquisita and 
bSLE: bullous systemic lupus erythematodus.
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Background Type VII collagen (coll VII) ELISA has been reported to have high sensitivity (>93%) 
and specificity (>96%) for diagnosing epidermolysis bullosa acquisita (EBA) patients who are 
seropositive by indirect immunofluorescence on salt-split skin (SSS). 
Objectives To investigate the added value of coll VII ELISA in the laboratory diagnosis of 
SSS-positive and SSS-negative EBA and to correlate the ELISA index with disease episode. 
Methods Coll VII ELISA was performed on banked sera of 28 EBA patients: 15 SSS-positive 
and 13 SSS-negative. Sera from healthy blood donors (n=17) and other autoimmune blistering 
diseases (n=29) served as controls. In four patients ELISA index was measured longitudinally. 
Serration pattern analysis by DIF was prospectively performed since 2000 and comprised 19 
patients.
Results The sensitivity in the SSS-positive group was 80% whereas it was 23% in the SSS-neg-
ative group. In the prospective EBA subset it was 45%. The sensitivity of u-serration pattern 
analysis on skin biopsy was 89%. Ten (53%) of these cases were seronegative by both ELISA 
and SSS, and would have been missed by serum analysis alone. Of the 46 control sera one 
serum tested positive (specificity 97.8%). The coll VII ELISA correlated with disease activity over 
time in individual patients. 
Conclusions Coll VII ELISA has limited added value in SSS-negative EBA cases. The ELISA test is 
very valuable in differentiating EBA from anti-laminin-332 MMP and anti-p200 pemphigoid and 
in its ability to serological monitor EBA patients. U-serration pattern analysis on IF skin biopsy is 
the gold standard for the diagnosis of EBA.
Introduction
Epidermolysis bullosa acquisita (EBA) is a subepidermal autoimmune blistering disease character-
ized by autoantibodies targeting type VII collagen (coll VII) that is the major structural compo-
nent of the anchoring fibrils of the epidermal basement membrane zone (BMZ). Clinically EBA 
can present as either the classic mechanobullous phenotype or as the inflammatory phenotype 
that mimicks other pemphigoid diseases as bullous pemphigoid, mucous membrane pemphigoid 
or linear IgA dermatosis.1 In the latter cases the diagnosis therefore relies on laboratory tests. In 
case of EBA immunofluorescence analysis of perilesional skin biopsies will show linear IgG BMZ 
deposits that have an unique u-serrated pattern in contrast to all other pemphigoid diseases 
where the deposits have a n-serrated pattern.2,3 Analysis of serum by indirect immunofluores-
cence may show IgG binding to the floor of salt-split skin (SSS) substrate and immunoblotting 
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may reveal IgG binding the 290-kDa antigen.4-7 In 1997 Chen et al. described a highly specific 
ELISA using the recombinant NC1 domain.8 Recently new ELISA’s for the detection of autoanti-
bodies against coll VII have emerged. A commercial ELISA is available that has the recombinant 
NC1 and NC2 coll VII domains coated to the plate, and high sensitivity (>93%) and specificity 
(>96%) has been reported 9,10 A correlation between coll VII ELISA index and disease severity 
was also demonstrated.10,11 Komorowski et al. used an ELISA plate containing only recombinant 
NC1 domain and reported a sensitivity of 98.7% and a specificity of 98.7%.12 All these studies 
relied on sera that were positive by SSS analysis.
To investigate how the type VII coll ELISA would contribute to diagnose EBA in a normal routine 
setting, we tested the banked sera of our EBA patients including the sera that were negative by 
SSS. Time sequence correlations of disease episode and ELISA values were investigated in four 
patients. 
Material and Methods 
Patient sera
Sera from EBA patients (n=28) were retrospectively selected from our biobank (Table 1). For the 
sera collected after 2000 the diagnosis of EBA was based on the following criteria: subepidermal 
mucocutaneous blisters and the u-serrated pattern of linear IgG BMZ deposits (#9-19, #21-23, 
#26-28). If no biopsy was available or if the serration pattern could not be defined patients were 
included based on the presence of subepidermal mucocutaneous blisters and serum binding to 
the dermal side of SSS and recognizing the 290-kDa antigen on immunoblot (#20, 24 and 25).
For the eight patients who were diagnosed with EBA before 2000, diagnosis was made for five 
by the combination of subepidermal mucocutaneous blisters, dermal SSS staining and positive 
immunoblot (#2-6). Furthermore two patients were included because of their classic generalized 
mechanobullous phenotype and dermal SSS staining (#7-8). One seronegative patient was 
included who had retrospectively been diagnosed with EBA in a case study (#1).13 Of all EBA 
patients diagnosed before 2000, the serration patterns of the IgG deposition were retrospec-
tively confirmed to be of the u-serrated type. As controls served sera from healthy blood donors 
(n=17) and from patients with other autoimmune blistering diseases (n=29).
43
3
Studies on clinical symptoms, diagnosis and treatment in pemphigoid diseases
44
3








1 F 70 Inf-BP u-serrated - - - + (22)
2 M 46 Mb-cMB u-serrated - dermal + -
3 F 74 Mb-BrPr u-serrated + dermal + + (73)
4 F 17 Inf-BP u-serrated + dermal + + (20)
5 F 64 Inf-BP u-serrated + dermal + + (45)
6 M 28 Inf-BP u-serrated + dermal + + (38)
7 M 67 Mb-cMB u-serrated + dermal - -
8 M 26 Mb-cMB u-serrated + dermal - + (59)
9 F 53 Inf-BP u-serrated - - - -
10 F 59 MB-cMB u-serrated - dermal + + (101)
11 F 31 MB-cMB u-serrated - - - + (10)
12 F 38 MB-cMB u-serrated + dermal - -
13 M 84 Inf-Pru u-serrated - - - -
14 M 31 MB-cMB u-serrated + dermal + + (101)
15 M 79 Inf-BP u-serrated - - - -
16 F 34 MB-cMB u-serrated - - - + (52)
17 F 37 MB-cMB u-serrated + dermal - + (129)
18 F 15 MB-cMB u-serrated + dermal - + (94)
19 M 69 Inf-BP u-serrated - - - -
20 F 87 Inf-MMP undetermined + dermal + + (58)
21 F 59 Inf-BP u-serrated - - - -
22 F 62 Inf-BP u-serrated - - - -
23 F 45 Mb-cMB u-serrated - - - -
24 F 18 Inf-BP na - dermal + + (182)
25 F 33 MB-cMB undetermined - dermal + + (15)
26 F 81 MB-cMB u-serrated - - - -
27 F 26 MB-cMB u-serrated - - - -
28 F 29 MB-cMB u-serrated - - - -
Table 1: Clinical and laboratory diagnostics of 28 patients with epidermolysis bullosa acquisita (#1-8 diagnosed retrospec-
tively before 2000; # 9-28 diagnosed prospectively from 2000).MB, mechanobullous phenotype; cMB, classic mecha-
nobullous; Inf, inflammatory phenotype; BP, bullous pemphigoid-like; MMP, mucous membrane pemphigoid-like; Pru, 
pruritus-like; M, male; F, female; DIF, serration pattern by direct immunofluorescence; MO, indirect immunofluorescence on 
monkey esophagus; SSS, indirect immunofluorescence on salt-split skin, +, positive; -, negative; n.a., not available
Type VII collagen ELISA
The anti-type VII collagen ELISA kit containing the recombinant NC1 and NC2 domains was 
used following the manufacturer’s protocol (MBL, Nagoya, Japan).
Index values over six were considered positive. 
Results
Fifteen of the 28 EBA sera (54%) had a positive ELISA index, median value 66.6 U/ml, range 
10-182 U/ml. Of the 15 SSS-positive patients 12 (80%) had a positive ELISA index (Table 1). 
To ascertain that the three with a negative coll VII ELISA (#2, #7, #12) did recognize type VII 
collagen we performed immunofluorescence knock-out analysis.14 Two sera (#7, #12) did not 
bind to coll VII deficient skin, but did bind to laminin-332 deficient skin confirming the presence 
of anti-coll VII antibodies. Of the third serum (#2), which had the lowest titre (1+) by SSS, the 
binding could not be determined due to background. This serum however had a positive immu-
noblot for the 290-kDa antigen. Of the thirteen sera that tested negative by SSS, three (#1, #11, 
#16) tested positive in the ELISA (23%). Of the 46 controls one serum tested positive what gives 
a specificity of 97.8 %. 
Since 2000 we prospectively performed serration pattern analysis. Of 19 patients we had 
biopsies available (#9-23, #25-28) and in 17 (89%) we identified the u-serrated pattern. For two 
cases the serration pattern was undeterminable, what for one case was due to the biopsy been 
taken from oral mucosa in which serration pattern analysis cannot be performed due to lack of 
overt basal cell rootlets.3
In this prospective EBA group (n=20; #9-28) coll VII ELISA was positive in nine cases (45%), and 
SSS was positive in eight cases (40%). Ten cases (50%) were seronegative by ELISA and SSS 
and would therefore have been missed if only serum tests had been used. The real sensitivity of 
ELISA and SSS for diagnosing EBA is therefore respectively 45% and 40% and combining those 
gives 50% sensitivity.




















































































HIVIG (2mg/kg/day: day 1-3)
Figure 1: Type VII collagen ELISA indices in relation to medication and disease episode in four patients with epidermolysis 
bullosa acquisita (1A:#17; 1B:#16; 1C:#3; 1D:#14). The dose of each medication is listed above the line. R: relapse; PR: 
partial remission: CR: complete remission; NR: no response; HIVIG: human intravenous immunoglobulin; Coll VII: type VII 
collagen
Discussion
For our SSS-positive sera we found a sensitivity of 80% which is lower than the >93% found in 
earlier studies.9,11,12 The three patients that tested negative clinically fitted the diagnosis mecha-
nobullous EBA. Since the knock-out immunofluorescence analysis demonstrated that at least two 
of the three sera did contain anti-coll VII antibodies, the conclusion must be that the recognized 
epitope(s) are not available on the ELISA plate
Interestingly, in our SSS-negative group 3 of 13 patients sera tested positive in the ELISA, 
although two sera had low ELISA titres. Chen et al. also found that SSS-negative patients tested 
positive in their ELISA.8
In serological positive patients, SSS IgG dermal binding in combination with positive immunoblot 
or ELISA, is sufficient to diagnose EBA. Since more than half of the EBA patients do not have 
detectable circulating antibodies by either SSS, immunoblot or ELISA, DIF serration pattern 
analysis on perilesional skin biopsy is mandatory for diagnosis in such cases. According to our 
results 89% of the EBA patients can be diagnosed by this method. If the serration pattern is 
undefinable, ELISA will find in 45% of such cases anti-coll VII autoantibodies. For the remaining 
cases that are positive by SSS analysis but negative by coll VII ELISA, a diagnosis of EBA can be 
reached by immunoblot and IF knock-out analysis.
We had consecutive sera of four patients and confirmed earlier studies where a correlation of 
ELISA and disease activity was described.9,10 Thus the coll VII ELISA test is a useful laboratory pa-
rameter for monitoring clinical activity. Another advantage of the ELISA test is that the diagnosis 
of EBA is direct and excludes anti-laminin-332 MMP or anti-p200 pemphigoid. 
In conclusion, coll VII ELISA is a valuable confirmative laboratory test for diagnosing and  
monitoring EBA, but it does not replace a skin biopsy for serration pattern analysis when 
suspecting EBA.
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Background Anti-laminin-332 mucous membrane pemphigoid (anti-LN-332 MMP) is a chronic 
subepidermal blistering disease characterized by IgG anti-epidermal basement membrane zone 
(BMZ) autoantibodies against laminin-332 (LN-332). Patients with anti-LN-332 MMP have 
an increased relative risk of malignancy. For diagnosis of anti-LN-332 MMP difficult to obtain 
laboratory techniques are needed.
Objectives To incorporate direct immunofluorescence (DIF) serration pattern analysis of IgG 
depositions in the diagnostic criteria of anti-LN-332 MMP. 
Methods Patients that met our revised inclusion criteria for anti-LN-332 MMP were selected 
from our biobank over the period 1997-2009. Inclusion criteria were clinical symptoms, DIF 
serration pattern analysis, indirect immunofluorescence on salt-split skin, and antigen-specificity 
analysis of the serum including immunoblotting and/or immunoprecipitation and/or ELISA 
against native LN-332. 
Results Ten patients met the inclusion criteria. A malignancy was found in two patients (20%). 
In all patients in whom it was performed (n=9), DIF showed linear IgG deposition along the BMZ 
in an n-serrated pattern. Nine sera reacted by salt-split skin analysis and bound to the dermal 
side of the split skin. ELISA against native LN-332 was positive in 77.8% of the tested sera. 
Conclusions Anti-LN-332 MMP can clinically resemble other forms of pemphigoid. Although 
state of the art laboratory diagnostics are necessary for definite diagnosis, the combination of 
simple DIF serration pattern and IIF salt-split skin analysis will exclude other forms of MMP and 
epidermolysis bullosa acquisita from the differential diagnosis. Because of the increased risk for 
malignancy patients should be thoroughly oncologically screened. 
Introduction
Domloge-Hultsch et al. were the first to describe a novel autoimmune subepidermal blistering 
disease with autoantibodies that bind epiligrin: anti-epiligrin cicatricial pemphigoid. Epiligrin 
appeared to be a mixture of laminin 5, now named laminin-332 (LN-332), laminin-6 (LN-311), 
and laminin-7 (LN-321).1,2 LN-332 is a heterotrimeric protein consisting of α3, β3 and γ2 
subunits (laminin α3β3γ2). LN-332 is present in the basal lamina of various epithelia including 
stratified squamous epithelium, and connects hemidesmosomes to anchoring fibrils by interlink-
ing integrin α6β4 to type VII collagen.3,4 In most patients with anti-LN-332 mucous membrane 
pemphigoid (anti-LN-332 MMP) the IgG autoantibodies predominantly target the LN-332 α3 
subunit, although IgG autoantibodies targeting the β3 or γ2 subunit have also been described.5,6 
Studies on clinical symptoms, diagnosis and treatment in pemphigoid diseases
52
4
The α3A subunit splice variant of LN-332 is similar to that in LN-311, and LN-321, implying 
that these laminin trimers are also crosstargets.7 Since LN-311, and LN-321 are relatively weakly 
expressed in the BMZ, and their β1 and β2 subunits have not been reported in autoimmune 
disease, for convenience of simplicity only LN-332 is assumed to be the autoimmune antigen in 
anti-LN-332 MMP. 
Anti-LN-332 MMP is clinically indistinguishable from other forms of MMP and presents with 
involvement of the mucosal surfaces of the mouth, eyes, nasopharynx, oropharynx, larynx and 
anogenital region.8-11 Approximately 5 to 20% of all MMP patients show circulating IgG autoan-
tibodies against LN-332.5,12 In most patients the skin is also involved, but usually less severe. An 
increased relative risk of cancer has been reported.5,13-17
The current diagnosis of anti-LN-332 MMP is based on criteria described previously: (i) chronic 
subepithelial blistering lesions of mucous membranes and skin, (ii) direct immunofluorescence 
(DIF) microscopy showing linear deposits of IgG with or without C3c along the BMZ, (iii) indirect 
immunofluorescence (IIF) microscopy showing IgG autoantibodies binding to the dermal side 
salt-split human skin, and (iv) circulating IgG anti-BMZ autoantibodies that immunoprecipate 
LN-332 from human keratinocyte extracts.18-20
In this study we present clinical and immunopathological findings in a cohort of 10 Dutch 
patients. Our data demonstrate a new algorithm to diagnose anti-LN-332 MMP based on the 
combination of clinical symptoms, state-of-the-art laboratory diagnostics and multidisciplinary 




Patients were selected from our database over the period 1997-2009. The following inclusion 
criteria for anti-LN-332 MMP were present: (i) subepidermal blisters and/or erosions on mucosal 
surfaces (ii) linear deposits of IgG along the BMZ in an n-serrated pattern – this separates 
anti-LN-332 MMP from epidermolysis bullosa aquisita (EBA) that is exclusively characterized 
by an u-serrated IgG deposition pattern –, (iii) circulating IgG autoantibodies that bind to the 
dermal side of 1-mol/L NaCL-split human skin – this separates anti-LN-332 MMP from other 
pemphigoid diseases of which the serum binds the roof of the split as for anti-BP180 MMP 
–, (iv) autoantibodies binding to LN-332 by either immunoblot, LN-332 ELISA, or immuno-
precipitation; – this separates anti-LN-332 MMP from anti-p200 pemphigoid as both diseases 
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are indistinguishable by DIF and IIF: both have an n-serrated IgG deposition in skin and both 
have serum antibodies that bind the floor of salt-split skin .21 The characteristics of the included 
patients are depicted in table 1.
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clinical remission with 
azathioprine 100 
mg/day







clinical remission with 
5 mg prednisolone
6 f 56 oral, anogenital localized prednisolone, azathioprine clinical remission with 
azathioprine 100 
mg/day
7 f 28 oral, ocular generalized prednisolone, azathioprine clinical remission 
without medicin
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Table 1: Clinical characteristics in 10 patients with anti-LN-332 MMP
Immunofluorescence microscopy
The technical procedure for immunofluorescence staining has been described in detail before.21 
Non-lesional skin, perilesional skin and/or mucosa biopsies were studied by DIF for BMZ 
deposits of IgG, IgA, IgM and C3c. The deposition pattern was typed as true linear, n-serrated 
or u-serrated. Serum samples were analysed by indirect immunofluorescence on both monkey 
esophagus and 1 mol/L NaCl-split human skin substrate. 
Immunoblot and immunoprecipitation
Immunoblot analysis was performed with extract of cultured human keratinocytes as described 
before.22 Immunoprecipitation was performed with extracts and medium from normal human 
keratinocytes radiolabeled with sulfur35–methionine.23,24
LN-332 ELISA
The LN-332 ELISA has been performed as described before.25
Results
Clinical manifestations
Ten patients were included. Eight of them had been treated by us, and of two patients’ blood 
and tissue samples had been sent to us from other hospitals for laboratory diagnostics. Five 
patients were male and five patients were female; mean age at onset of symptoms was 50 
years (range 23-78 years). The mean age at date of diagnosis was 51.1 years (range 25-78 
years). Delay in diagnosis ranged from 2 to 48 months. In one exceptional case the patient had 
complaints of epistaxis and oral ulcerations for four years, before she was referred to our hospital 
and was diagnosed anti-LN-332 MMP. The mean follow up of the patients was 8.3 years (range 
3-14 years).
The clinical symptoms included involvement of the skin (n=8), oral (n=8), nasal (n=6), ocular 
(n=7), pharyngeal (n=6), laryngeal (n=3) and anogenital (n=2) regions respectively (Fig 1 and 
table 1).
Skin symptoms consisted of recurrent bullae and erosions on the trunk and extremities. In cases 
#3, 7 and 9 blistering was generalized. Oral lesions consisted of desquamative gingivitis and 
ulcerations, sometimes leading to pain hampering oral intake.  
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Nasal involvement was apparent by epistaxis and intra-nasal crustae. Ocular involvement led to 
conjunctivitis, eye dryness with a burning sensation, and symblepharon. In patient #1, pannus 
formation resulted in blindness of one eye. In three patients the larynx was involved which led 
to hoarseness and dyspnoea because of ulcerations and erosions on the vocal folds (Fig 2). 
In patient #2 cicatrizing laryngeal lesions resulted in airway stenosis - he needed a life saving 
tracheotomy. 
A malignancy was found in two out of ten patients (20%): both had adenocarcinoma of the 
lung. In one patient the lung carcinoma was diagnosed one year after the start of the mucocu-
taneous blistering. Interestingly, complete clinical remission of the anti-LN-332 MMP was seen 
after complete remission of the lung carcinoma. Detailed information on the other patient was 
not available.
Eight of ten patients were treated at our clinic. All eight patients received systemic cortico-
steroids (prednisolone 40-60 mg/day). In four patients dexamethasone pulse therapy (three 
consecutive days 300 mg a day orally or 200 mg a day intravenously) was added in one or two 
cycles because of unresponsiveness to prednisolone (#1-4) or severe laryngeal stridor (#5). In 
one patient clinical remission was achieved after dexamethasone pulse therapy. In the other 
four patients clinical symptoms improved dramatically, although adjuvant immunosuppressive 
drugs was needed after months. Other adjuvant immunosuppressive drugs used were dapsone, 




Figure 1: Clinical features in anti-LN-332 MMP patient #1. (A) Conjunctivitis with symblepharon and oedema of the upper 
eyelid (B), extensive blistering of the oral mucosa (C), erosions on nasal mucosa (D), genital ulcers.
Figure 2: Laryngeal cicatrization of the aryepiglottic folds with supraglottic stenosis in patient #5 (A), and in healthy control. 
Top is ventral side of patient (B).
Laboratory diagnostics
DIF showed for 9/9 biopsied patients linear IgG deposition along the BMZ in an n-serrated 
pattern. Complement C3c deposition in the BMZ was present in 7/9 patients (77.8%) and IgA 
deposition in 2/9 patients (22.2%). IIF of serum on monkey esophagus showed circulating 
anti-BMZ IgG in 6/10 patient sera (60%). On salt-split skin 9 of the 10 sera (90%) bound to the 
dermal side of the split. (Table 2)
Immunoblot analysis on keratinocyte extract demonstrated binding to the unprocessed 200-kD 
and processed 165-kD laminin α3 chain for 5/10 sera (50%). Immunoprecipitation was only 
performed for two sera and one of these immunoprecipitated LN-332 (50%). ELISA against 
native LN-332 was positive in 7 of 9 tested sera (77.8%). In patient #3 ‘knock-out’ analysis was 
positive in  type VII collagen deficient skin from a patient with dystrophic epidermolysis bullosa 
and LN-332 negative skin from patient with Herlitz-type junctional epidermolysis bullosa. In this 
patient immunoblot analysis revealed IgG reactivity to the 290-kd type VII collagen and to the 
unprocessed 200-kD and processed 165-kD laminin α3 chain.
Studies on clinical symptoms, diagnosis and treatment in pemphigoid diseases
58
4
Patient DIF IIF SSS IB ELISA 
LN-332
IP Knock-out FOAM
1 n-serrated + dermal LN α3 + np np np
2 n-serrated - dermal LN α3 + np np np
3 n-serrated + dermal LN α3
Coll VII
+ Coll VII +
LN-332 +
np
4 n-serrated + dermal LN α3 + np Coll VII + LN-332 - +
5 n-serrated + dermal - + np np np
6 n-serrated + dermal - - np np np
7 n-serrated + dermal LN α3 - np np np
8 n-serrated - dermal - + np np np
9 na - dermal - + np np np
10 n-serrated - - - np LN-332 np np
Table 2: Laboratory diagnostics of 10 patients with anti-LN-332 MMP. DIF: Direct immunofluorescence. (n- or u-serrated 
pattern); IIF: Indirect immunofluorescence; SSS: Salt-split skin analysis (epidermal or dermal binding); IB: Immunoblot; IP: 
Immunoprecipitation; na: not available; np not performed
Discussion
In this series of 10 Dutch anti-LN-332 MMP patients we found variable clinical symptoms with 
more pharyngeal and laryngeal involvement (60%) than is expected in other types of MMP. We 
added DIF serration pattern analysis to the previously described diagnostic criteria.18-20   
Furthermore we promote aggressive treatment in a multidisciplinary team because of the 
scarring phenotype of anti-laminin-332 MMP.
Clinical symptoms
Mucosal lesions were seen in 100% of the patients in our series. The oral mucosa and eyes were 
affected mostly, combined in 50% of all cases. This is in agreement with the results obtained by 
Egan et al. who described oral mucosa and eyes as predominantly affected with nose, throat and 
anogenital regions less frequently.5 The first clinical symptoms like nasal crustae, genital erosions 
or shortness of breath can mimic other forms of MMP including EBA, and immunopathologic 
evaluations therefore are of great importance. Wozniak et al. described a case that started 
with exclusive involvement of the upper respiratory tract that led to progressive dyspnoea and 
respiratory airway obstruction. After one year oral lesions and scarring conjunctivitis appeared.26
Skin lesions were seen in 8 of our 10 patients. Five patients had localized blistering and in 3  
patients generalized blistering were seen. Skin lesions are not the dominant feature in  
anti-LN-332 MMP. Two patterns of skin blistering have been described before: (i) generalized 
bullous pemphigoid-like blistering and (ii) localized Brunsting-Perry-pemphigoid-like vesiculation 
at the scalp, head, neck and upper trunk.19
Scarring of the eyes is a serious aspect of anti-LN-332 MMP. Most of our cases presented with 
symblepharon and the conjunctivitis/keratitis evoked a burning sensation in the eyes. Coronella 
et al. described the first case of anti-LN-332 MMP that had only ocular involvement with 
erythema and oedema of the eyelids but without subconjunctival fibrosis and scarring. This case 
responded excellent to treatment with methylprednisolone and dapsone.27 Eye involvement 
necessitated aggressive treatment to prevent scarring. The emotional consequences of antici-
pated blindness must not be underestimated. One of our patients committed suicide because 
of progressive loss of sight of both eyes. In such cases emotional support by a multidisciplinary 
team is a necessity.
Airway obstruction due to pharyngeal and laryngeal involvement is a serious complication that 
is seen more in anti-LN-332 MMP than in other forms of MMP.28, 29 First manifestations are 
aphonia (loss of voice) due to oedema, erosions and ulcerations of the supraglottic area. This is 
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followed by scarring of the larynx, and acute upper airway obstruction due to initial laryngeal 
oedema may occur, necessitating tracheotomy.5 
Other mucosal surfaces that may be affected include those of the nose, esophagus, genitals and 
anus.5,12 Esophageal involvement is described but is most often asymptomatic and probably un-
der diagnosed. When scarring causes stenosis, then dysphagia, phagodynia and gastroesopha-
geal reflux may result. The incidence of esophageal involvement in cicatricial mucous membrane 
pemphigoid has been estimated to be approximately three percent.30
Malignancy
Patients with anti-LN-332 MMP have an increased relative risk for malignancy.5,13,31,32 Egan et al. 
described a cohort of 35 patients in which 29% had a solid cancer. The relative risk for malig-
nancy was calculated as 6.8%. Lung cancer and stomach cancer were found mostly.5 Sadler et 
al. described 15 anti-LN-332 MMP patients with an associated malignancy. The time between 
blister onset and cancer diagnosis was 14 months in 12 of the 15 patients. In the other three 
patients a malignancy was diagnosed several years before or after anti-LN-332 MMP. Adeno-
carcinoma was found most frequently with five patients having a lung carcinoma.13 In our study 
two out of ten patients had an adenocarcinoma of the lung (follow up 8.3 years, range 3-14 
years).  
Treatment
Patients with anti-LN-332 MMP must be treated promptly and adequately to achieve control 
of disease and to delay progression. A multidisciplinary approach is a necessity when multiple 
mucosal sites are affected. In our Centre for Blistering Diseases we have an intense standard 
cooperation with the ophthalmologist and otolaryngologist for these patients. 
Treatment used is always a combination of systemic corticosteroids (prednisolone) and a steroid 
sparing adjuvant. For acute crisis management, we advise dexamethasone pulse therapy. 
Azathioprine and cyclophosphamide are preferred choice when ocular involvement is present.33,34 
In our centre azathioprine (3 mg/kg body weight/day) is first choice of therapy as steroid 
sparing drug. Thiopurine methyltransferase (TPMT) activity must be measured before starting. 
Therapeutic effect may only be evident after weeks or months. Cyclophosphamide either daily 
(2 mg/kg body weight/day) or pulsed (750 mg/m² every month intravenous) gave good results. 
Since cyclophosphamide is a known risk factor for haemorrhagic cystitis and for bladder cancer, 
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superfluous fluid intake and urine screening is needed. Other immunosuppressant drugs given 
include dapsone, mycophenolate mofetil, mycophenolic acid, intravenous immunoglobulins and 
rituximab.
Laboratory diagnostics
Given the disease course and the increased risk of malignancy it is important to distinguish 
anti-LN-332 MMP from other forms of MMP including the mucosal predominant forms of 
epidermolysis bullosa acquisita (EBA). In another paper we described how to differentiate EBA 
from all other subepidermal blistering diseases by DIF serration pattern analysis.21 Three distinct 
‘linear’ BMZ deposition patterns are recognized: true linear, n-serrated and u-serrated. We speak 
of a true linear deposition pattern when no serration pattern is present. This is found in mucosa, 
but can also be present in skin after corticosteroid treatment. The u-serration pattern is found 
when the autoantibodies bind to type VII collagen as in EBA and bullous systemic lupus erythe-
matosus, including IgA-deposition in IgA-EBA. An n-serrated deposition pattern occurs due to 
binding of autoantibodies to all other known pemphigoid antigens, the hemidesmosomal BP230, 
BP180, plectin and LAD-1, and the lamina lucida orientated LN-332 chains and the LN γ1 chain. 
In our study all patients showed deposition along the BMZ in an n-serrated pattern, thereby 
excluding EBA (Fig 3)  
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Figure 3: (A+B): Direct immunofluorescence staining of IgG in perilesional skin: (A) n-serration -anti-LN-332 MMP- and (B) 
u-serration -epidermolysis bullosa acquisita- (C+D): Immuno-electron microscopy IgG: (C) Supra-lamina densa IgG and (D) 
Sub-lamina densa IgG
The next step is salt-split skin analysis of the serum by indirect IF microscopy. This excludes the 
MMP forms with hemidesmosomal antigens as BP180. As these are located in the roof of salt-
split skin, all sera that bind the roof can be considered not to be anti-LN-332 directed. Of our 
sera nine bound the floor of the salt-split while one did not bind at all. 
The last step is to separate anti-LN-332 MMP from anti-p200 pemphigoid what can be done by 
immunoblot, ELISA or immunoprecipitation. 
In our patients a positive identification of anti-LN α3 antibodies could be made by immunoblot 
analysis for five out of ten cases (50%). Previous studies have indicated that the α3 subunit is 
the major antigenic domain in cases of anti-LN-332 MMP 23,35, although others have argued 
that the reactivity of anti-LN-332 MMP sera is more heterogenous.36 Fujimoto et al. described 
a patient with combined IgG binding to the laminin β3 and γ2 chains.37 Endo et al. described a 
patient without mucosal involvement and autoantibodies against LN-332 γ2 subunit.38
ELISA against native LN-332 was positive in 7/9 cases (77.8 %). Sensitivity and specificity of the 
LN-332 ELISA for MMP is 75% and 84.3%, respectively.25
When omitting the last step, we could diagnose anti-LN-332 MMP or anti-p200 pemphigoid 
in 9 out of 10 patients by using simple DIF and IIF. Moreover, patient #6, who was negative in 
ELISA and immunoblot, could be included because of the n-serrated pattern in DIF and circu-
lating IgG autoantibodies that bind to the dermal side of salt-split skin. anti-p200 pemphigoid 
could formally not be excluded on these laboratory results, but the mucosal dominant clinical 
presentation makes a diagnosis of anti-LN-332 MMP likely. The clinical presentation of anti- 
p200 pemphigoid is aspecific and may mimic bullous pemphigoid (most common), linear IgA 
dermatosis or dermatitis herpetiformis.39,40 
If no biopsy is available or if serration is absent in the biopsy, the diagnosis has to be established 
through serum analysis. If immunoblotting, immunoprecipitation or ELISA is not available some 
valuable information can be obtained through indirect immunofluorescence. First, salt-split 
skin analysis has to demonstrate that the serum binds to the floor of the split. EBA can then be 
excluded by fluorescence overlay antigen mapping (FOAM), which is double staining of the 
serum with monoclonals for respectively type VII collagen and for LN-332.41,42 Secondly, it is 
also possible to perform ‘knock-out’ analysis. This is indirect immunofluorescence analysis on 
antigen-deficient skin, in this case type VII collagen deficient skin from patients with dystrophic 
epidermolysis bullosa, and LN-332 deficient skin from patients with Herlitz-type junctional 
epidermolysis bullosa.43 In patient #3 ‘knock-out’ analysis was positive in both type VII colla-
gen-deficient and LN-332-deficient skin, while immunoblot analysis also revealed IgG reactivity 
to the 290-kd type VII collagen and to the unprocessed 200-kD and processed 165-kD laminin 
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α3 chain. This patient has had a combination of anti-LN-332 MMP and the inflammatory 
variant of EBA.24
Criteria to diagnose anti-LN-332 MMP
The current diagnosis of anti-LN-332 MMP is based on criteria described previously.18-20 New 
insights, as described in this article, leads to additional criteria to diagnose anti-LN-332 MMP:
Major criteria:
1) Subepithelial erosions or blisters on mucous membranes frequently associated with scarring 
phenotype,
2) IgG depositions along the BMZ in the n-serrated pattern by DIF,
3) IgG bound to the dermal side of 1-mol/L NaCL-split human skin by IIF,
Minor criteria:
1) Anti-LN α3, β3, or γ2 IgG binding by immunoblot analysis on keratinocyte cell extract,
2) IgG reactivity to native LN-332 by ELISA,
3) Serum immunoprecipitation of LN-332 trimer,
4) Negative IIF on LN-332 deficient skin, while positive IIF on type VII collagen deficient skin,
5) IgG BMZ deposits overlay LN-332 by fluorescence overlay antigen mapping (FOAM).
To diagnose anti-LN-332 MMP at least three major criteria, or two major criteria and one minor 
criterion must be obtained. 
Conclusion
We describe a new algorithm to diagnose anti-LN-332 MMP. Because of the scarring pheno-
type, it is important to establish diagnosis in an early stage and to start aggressive treatment 
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In literature, patients with bullous pemphigoid (BP) have been reported with itch without 
blisters. Clinical observations in these patients varied from eczematous or urticarial to papular or 
nodular skin lesions. Here we investigated the spectrum of clinical variants.
Observations
Fifteen patients presented with itch without blisters, but immunopathological findings of BP. 
Mean age at diagnosis was 81.7 years. No blistering occurred during 2.2 years of follow up. 
Mean delay of diagnosis was 2.8 years. Clinical symptoms were heterogeneous: pruritus sine 
materia (no primary skin lesions), eczematous, urticarial, papular and/or nodular skin lesions 
were seen. Treatment with potent topical corticosteroids or methotrexate sodium led to remis-
sion in eleven patients. 
Conclusions and Relevance
Itch without skin lesions (pruritus sine materia) can be the only symptom of BP. Therefore it is 
important to include serological and direct immunofluorescence in the diagnostic algorithm of 
itch. We propose the unifying term ‘pruritic nonbullous pemphigoid’ in the spectrum of BP for all 
patients with immunopathological findings of BP, itch and no blisters. 
Introduction
Bullous pemphigoid (BP) is the most common subepidermal autoimmune blistering disease 
(sAIBD) characterized by autoantibodies targeting the 180-kD bullous pemphigoid antigen 
(BP180, BPAG2, or type XVII collagen), and/or 230-kD bullous pemphigoid antigen (BP230, 
BPAG).1 Elderly are more frequently affected and the associated morbidity is significant. In the 
recent “Definitions and outcome measures for bullous pemphigoid” pruritus, urticaria and tense 
blisters were reported as the three main clinical pillars of BP.2 Diagnosis of BP is commonly based 
on the combination of clinical presentation, histopathology, direct immunofluorescence (DIF) and 
the serological detection of autoantibodies by indirect immunofluorescence (IIF) and/or identifi-
cation of the involved autoantigens.1-4 Previous studies have described patients with pruritus and 
immunopathological findings of BP but no blister development.5-9 As a result, pruritus alone or 
non-bullous skin lesions are frequently misdiagnosed as xerosis, drug reaction, dermatitis, renal 
impairment, liver impairment or scabies in elderly patients. In this study we describe a series of 
patients derived from our biobank database with immunopathological findings of BP who had 
pruritus sine materia or pruriginous skin lesions without blisters. 
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Patients meeting the criteria were selected over the period 2002-2012 from the biobank of 
the Centre for Blistering Diseases in Groningen, the Netherlands. The inclusion criteria were: (i) 
no blisters, (ii) with either depositions of IgG and/or C3c along the BMZ in the n-serrated or 
indefinable pattern, or a positive salt-split skin analysis (SSS) with binding to the epidermal side 
of the blister in combination with a positive NC16A ELISA or a positive BP230 ELISA.
We included one patient (#11) with SSS epidermal binding without any other confirming 
positive test for BP. This patient was included because of clinical features correlating with pruritic 
non-bullous pemphigoid and after exclusion of other pruritic disorders (as eczema and drug 
reactions).
Lesional, perilesional and/or non-lesional skin biopsies were studied by DIF for BMZ depositions 
of IgG, IgA, IgM and C3c, as described before.4 Sera of patients were tested by IIF on both 
monkey esophagus and human salt-split skin substrate.4
Immunoblot analysis was performed with extract of cultured human keratinocytes as described 
before.3 The anti-NC16A and anti-BP230 ELISA (both from MBL, Nagoya, Japan) were per-
formed according to the protocols of the company. Index values <9 U/mL were 
considered negative.
Reports of Cases
Fifteen patients met our inclusion criteria, all complained of severe itch. This comprised 12% of 
all patients diagnosed with BP in our biobank (n=130). Mean age at onset of symptoms was 
78.9 years (range 44-93 years). Except for two patients (age 39 and 64 years), all were older 
than 70 years. Mean age at diagnosis was 81.7 years (range 39-95 years). Mean delay of diag-
nosis was 2.8 years (range 6 months-11 years). In one case, the patient had pruritic symptoms 
lasting 11 years that were considered eczema prior to correct diagnosis. The mean follow up 
time was 2.2 years (range three months-eight years). 
Twelve patients had pruritus and excoriations with pruriginous skin lesions comprising eczem-
atous lesions, urticarial plaques, erythematous papules or nodules (Table 1). The distribution 
varied from the extremities (n=7), localized on trunk (n=2) to generalized (n=3). 
Three patients only suffered from pruritus sine materia, in whom linear excoriations were the 
only visible manifestation of disease (Fig 1). Eleven patients had at least one biopsy with positive 
DIF that had IgG and/or C3c BMZ deposition. Of seven patients the serration pattern was of 
the n-type (#1-2, #5, #7, #12, #14-15) while in four cases (#6, #8-9, #13) the pattern was 
indefinable. DIF was performed on lesional skin (6 out of 7 positive), perilesional skin (3 out of 
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5 positive), or healthy skin (2 out of 7 positive) (Table 2). In one patient, DIF from perilesional 
skin was negative, whereas positive from lesional skin. Four patients had negative DIF, but had 
positive IIF showing IgG circulating autoantibodies on monkey esophagus and SSS (epidermal 
binding). Immunoblot on BP180 was negative in all but one patients; immunoblot on BP230 
was positive in five patients. NC16A ELISA was positive in five patients (range index 13-29 U/
mL) and BP230 ELISA in nine patients, range index 16-71 U/mL (Table 2). Routine histology was 
performed for 12 patients and was either non-specific (#1-2, #4, #8, #11, #14) or showed spon-
giotic dermatitis with eosinophils (#6-7, #10, #12-13, #15). In all patients treatment was started 
with potent topical corticosteroid application over the entire body: clobetasol propionate 0.05% 
cream or momethason furoate 0.1% cream. The dosage of the potent topical corticosteroid 
was 20 g/d in the first month, 20 g every other day in the second month, 20 g twice a week in 
the third month, and 20 g once a week in the fourth month. Six of 15 patients reached clinical 
remission while receiving this treatment. Methotrexate (MTX) at a dose of 5-15 mg weekly in 
combination with folic acid 5 mg two days after intake was given in six out of nine patients 
who did not respond on topical corticosteroid therapy (Table 1). Five patients reached clinical 
remission on this therapy. The sixth patient did not tolerate MTX due to facial edema. Additional 
treatment with prednisolone 20 mg daily in combination with mycophenolate-mofetil 500 mg 
once daily also appeared insufficient. Patient 11 died of cardiac failure that was not related to 
the disease or treatment. Three patients, who did not respond on topical corticosteroid therapy, 
reached clinical remission on low dose oral prednisolone (5-7.5 mg daily). One of them received 
additional azathioprine 100 mg/day.
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Patient Sex Age Clinical symptoms Therapy
1 M 87 pruritus sine materia prednisolone 10 mg + MTX 10 mg
2 M 88 pruritus sine materia methotrexate 10 mg
3 F 64 pruritus sine materia clobetasol propionate 0.05% cream
4 F 82 eczematous lesions clobetasol propionate 0.05% cream
5 M 94 eczematous lesions clobetasol propionate 0.05% cream
6 M 95 eczematous lesions prednisolone 7.5 mg +  azathioprine  100 mg
7 F 88 eczematous lesions clobetasol propionate 0.05% cream
8 F 39 eczematous lesions, papules methotrexate 7.5 mg
9 F 87 papules clobetasol propionate 0.05% cream
10 F 79 papules clobetasol propionate 0.05% cream
11 M 94 papules non response
12 F 92 papules clobetasol propionate 0.05% cream + methotrexate 5 mg
13 M 71 papules, nodules methotrexate 15 mg
14 M 87 papules, nodules momethason furoate 0.1% cream + prednisolone 7.5 mg
15 M 80 urticarial lesions prednisolone  5 mg
Table 1: Clinical characteristics and therapy of 15 pruritic nonbullous pemphigoid patients
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Figure 1: Clinical presentations of pruritic nonbullous pemphigoid by (A) pruritus sine materia (patient 2), (B) urticarial 
plaques (patient 15), (C) eczematous lesions (patient 6), and (D) excoriated nodules (patient 13)


















1 IgG+ H IgG+ IgG3+ - - - 23
2 IgG+ H - - - - - 59
3 - H IgG+ IgG2+ - +/- 29 30




H - IgA+ - - - -
6 IgG+/2+ L - - - - 17 -
7 IgG2+ 
C3c2+
L IgG+ IgG+ + + 27 71
8 IgM, IgG+ L IgG+ IgG+ - - - -
9 IgA+IgG+ 
C3c2+
L IgG+ - - - - -
10 - P, H IgG+ IgG+ - - 23 19
11 - P, H IgG+ IgG2+ - - - -
12 IgG+ L IgG+ IgG2+ - + - 34
13 C3c 2+ L IgG+ IgG2+ - +/- 13 38
14 IgG+ P - - - - -
15 IgG+ C3c+ P IgG+ IgG3+ - - - 16
Table 2: Immunodermatological findings in 15 pruritic nonbullous pemphigoid patients.
Comment
BP may start with pruritus in the prodromal stage, while blisters develop weeks or months 
later.1,10-14 In a Swiss study population 20% of 160 diagnosed BP patients presented without 
blisters.15 In the literature patients have been reported with itch combined with immunopatho-
logical findings compatible with BP but without the formation of blisters, when followed up for 
several months or even years.5-9,11,14,16-19 In previous studies most of these patients were elderly 
with an age above 70 years (follow up four months- six years). In the present study mean age 
was 81.7 years. According to the definitions from an international expert panel, the symptom 
pruritus is considered to be sufficient for the diagnosis of BP, if the immunological criteria are 
met.2
Pruritus is also component of the subjective Bullous Pemphigoid Disease Area Index (BPDAI).  
Among all patients with pemphigoid in our Centre for Blistering Diseases about one in eight did 
not develop blisters, while all of them experienced itch. The skin symptoms consisted of ery-
thematous, excoriated papules or nodules and urticarial or eczematous plaques. Three out of 15 
patients (20%) only had pruritus without primary skin lesions (pruritus sine materia). This implies 
that a dermatologist who sees an elderly patient with unexplained itch, even without evident 
skin manifestations, should think of BP. In such case one should perform both IIF and DIF.
Diagnosis was reached by a positive DIF with IgG and/or C3c along the epidermal BMZ, or 
SSS-epidermal binding in combination with a positive ELISA (NC16A or BP230). Earlier studies 
reported individual cases suggestive of BP in the absence of a positive DIF.5,20 Additional findings 
included a positive IIF on monkey esophagus or detection of BP180 or BP230 autoantibodies 
by immunoblot. Our ELISA results concord with Feliciani et al. who found that BP230 ELISA is 
more often positive than NC16A ELISA.20 In our study we found more positive DIF results from 
biopsies of lesional skin than those of perilesional or healthy skin. In one case perilesional DIF 
from healthy skin was negative while lesional DIF from a papule was positive. Future studies 
should point out if a lesional DIF biopsy for this group of patients is indicated, instead of perile-
sional which is recommended for BP.21 Histopathology is either nonspecific or shows spongiotic 
dermatitis with eosinophils, which can be suggestive for BP.5-7,17 
In the literature there is no unanimity on how to name this subset of patients. The coined terms 
include ‘pruritic pemphigoid’, ‘pemphigoid nodularis’, ‘papular pemphigoid’, ‘prurigo-nodularis 
like pemphigoid’, ‘nonbullous BP’, ‘prodromal BP’ and ‘BP incipiens’.5-7,9,20,22,23 In our opinion the 
latter two can be used only retrospectively when blisters have appeared. Furthermore, lesions 
that may accompany the pruritus were heterogeneous. The term nonbullous pemphigoid seems 
adequate, but lacks the most important clinical characteristic: pruritus. We therefore propose the 
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unifying term ‘pruritic nonbullous pemphigoid’, to trigger the dermatologist to think of pemphi-
goid when confronted with an elderly who complains of itch.
Treatment of this intense pruritic condition is essential. In line with previous authors we suggest 
a therapeutic ladder starting with whole body application of potent topical corticosteroids as 
clobetasol propionate cream.6,20,24 If non-responding, our preferred treatment is MTX in a low-
dose prescription (5-15 mg a week) corresponding with treatment of BP.25-27 When insufficient a 
wide range of other therapeutic options have proven successful in the past.5-9,17,18,20 
Progression of pruritic nonbullous pemphigoid to bullous pemphigoid rarely occurs.6,28 The most 
intriguing question is why these patients do not develop blisters. When antigens were identified 
it was mostly BP230.29,30 Rabbit and mouse model studies showed that BP230 autoantibodies 
induce skin fragility but do not lead to development of blisters. Another explanation might be 
that IgE autoantibodies against BP180,31 induce pruritus, while IgG along the BMZ is insufficient 
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Background Current standard of treatment of bullous pemphigoid (BP) is systemic oral cortico-
steroids (CS). However significant iatrogenic morbidity and mortality is reported. Studies have 
shown that topical potent CS is safer than oral prednisolone in BP.  
Objectives To examine the local and systemic efficacy and adverse effects of whole body 
clobetasol propionate cream application in patients with mild or severe BP. 
Methods Open, clinical records-based retrospective analysis of a series of mild (n=40) and severe 
(n=34) BP patients, treated with ranging doses (20-40g/day) clobetasol propionate cream. For 
assessing systemic effects we observed in selected cases eosinophil count and morning urine 
cortisol level. 
Results Patients with mild BP achieved in 90.0% disease control and in severe BP in 73.5%. 
Complete remission was achieved in mild BP in 64.1% (35.9% off therapy and 28.2% on ther-
apy) versus 41.2% in severe BP (5.9% off therapy and 35.3% on therapy). Local adverse effects 
were mainly skin atrophy (14.9%) and purpura (5.4%). Systemic adverse effects were rare (n=3) 
and consisted of deep vein thrombosis, hypertrichosis and adrenocortical insufficiency. Systemic 
effect was witnessed by immediate drop of eosinophil count, and decrease in the morning urine 
cortisol in selected cases.
Conclusions Topical whole body application of clobetasol propionate cream as monotherapy can 
be effective and safe in the induction phase of treatment in mild BP and severe BP. When relapse 
occurs adjuvant systemic medication is mandatory. Potent CS works locally and systemically 
against BP, at the price of significant local and less significant systemic adverse effects.
Introduction
Bullous pemphigoid (BP) is an acquired subepidermal autoimmune blistering disease (AIBD) 
preferentially in elderly characterized by pruritic eruption of bullae, urticaria, erythema or 
papules.1,2 The targets of the autoantibodies are 180-kD bullous pemphigoid antigen (BP180, 
BPAG2, or type XVII collagen), and/or 230-kD bullous pemphigoid antigen (BP230, BPAG1).3,4 
These are components of the hemidesmosomal plaque, adhesion structures that anchor the 
basal cells to the underlying epidermal basement membrane zone (EBMZ). Patients with BP 
almost always present with itch and some with urticarial plaques that may evolve into vesicles 
and blisters.5 Treatment of BP is challenging because of the older age of the patients, and the 
comorbidities like neurological and cardiovascular disorders that are associated with the age 
and the disease.1 Multiple drugs are often used, whereas these patients are at high risk of 
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adverse drug reactions and side-effects.1,2,6-8 Treatment can be divided into two groups: i) topical 
application of potent corticosteroids (CS) -clobetasol propionate cream- or ii) systemic oral CS 
with or without steroid sparing immunosuppressive drug. Systemic oral CS is the best established 
treatment according to current evidence,5 but iatrogenic morbidity and mortality is reported. 
Potent topical CS should be considered in any patient with BP.9 
Recently, French colleagues assembled in the ‘Groupe Bulle’ conducted two randomized 
controlled trials in BP, and showed that topical clobetasol propionate cream application on the 
whole body, progressively tapered over 12 or four months, were both effective while reducing 
the morbidity in severe BP due to treatment.6,10 
It is likely that the high efficacy of whole body topical clobetasol propionate application is due 
to both local and systemic effects. However systemic oral CS raised more adverse effects (54%) 
than topical clobetasol (29%).6 
In this study we examined the efficacy and adverse effects of whole body topical clobetasol 
propionate cream application in patients with mild or severe BP. Moreover we investigated 




Potent topical CS therapy started in 2002 at the Centre for Blistering Diseases in Groningen after 
the publication of Joly et al.6 For the current study, patients with diagnosis of bullous pemphi-
goid were selected from our biobank over the period 2002-2010 using the following criteria: 
i) subepidermal blistering and/or erosions of the skin, and ii) DIF showing deposits of IgG along 
the EBMZ in the n-serrated pattern, and/or iii) autoantibodies binding to BP180 and/or BP230 
either by immunoblot or NC16A-ELISA. All files of BP patients in this period were examined 
and those patients that had received potent topical CS were included. In case of missing data 
patients were excluded.
Patients were divided into two groups: i) mild BP and ii) severe BP, and were compared for the 
local and systemic efficacy and adverse effects of clobetasol propionate cream. This selection 
was determined on the number of bullae that were seen at the day of the first consultation. Mild 
BP was defined by <10 bullae and severe BP by ≥10 bullae according to Joly et al.6 Patients with 
mild BP were treated with an initial ranging dose of 20-40 g/day clobetasol propionate cream. 
Patients with severe BP were also treated with an initial ranging initial dose of  
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20-40 g/day clobetasol propionate cream (Table 1). The clobetasol propionate cream was 
tapered in four months according to the following protocol: first month clobetasol propionate 
cream every day, second month every other day, third month twice a week and fourth month 
once a week. 
Osteoporosis prophylaxis or antacids were not routinely given. Few patients who received 
steroid sparing immunosuppressive medication besides potent topical CS were also included. 
Adjuvant medication was started after disease control when after a relapse potent topical CS 
was not enough to control the disease.
Primary outcomes
Outcome measures as defined by the recent international consensus were used.5 Primary 
outcomes were: disease control and remission. Disease control was defined as: the time interval 
from baseline to the time at which new lesions cease to form and established lesions begin to 
heal or pruritic symptoms start to abate. Remission was divided into three groups: i) complete 
remission (CR) off therapy, ii) CR on therapy and iii) partial remission (PR). CR off therapy was 
defined as the absence of new or established lesions or pruritus while the patient is off all BP 
therapy for at least two months; CR on therapy as the absence of new or established lesions 
or pruritus while the patient is receiving minimal therapy (less than 10mg prednisolone and/or 
adjuvant), not for at least 2 months and PR is defined as the presence of transient new lesions 
that heal within one week without treatment or pruritus less than once per week.
Secondary outcomes
Secondary outcomes were relapse, adverse effects, eosinophil count and pharmaco-economics. 
A relapse was defined as the appearance of three or more new lesions a month (blisters, eczem-
atous lesions or urticarial plaques) or at least one large (>10cm diameter) eczematous lesion or 
urticarial plaques that do not heal within one week, or the extension of established lesions or 
daily pruritus in a patient who has achieved disease control. In patients who had a relapse during 
the period when the dose was being reduced, the dose was increased to the previous level that 
had permitted control of the disease. Adverse effects were divided into local (like skin atrophy, 
striae or purpura and others) and systemic adverse effects (like adrenocortical insufficiency, 
diabetes mellitus, cardiovascular and neurovascular disorders or infections and others). Eosinophil 
count was determined at the start of the treatment (in 10^9/l) and was measured within the 
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next 12 days in nine selected cases. These patients did not receive any other medication than 
topical potent CS. Medication costs were calculated by sum up the costs of daily clobetasol pro-
pionate cream treatment in mild and severe BP patients. These results were compared with the 
costs of oral CS, osteoporosis prophylaxis and antacids treatment in mild and severe BP patients.
Morning urine cortisol (nmol/l)
In three patients morning urine cortisol (nmol/l) was measured. The first patient received a 
treatment of 30 g triamcinolone acetonide 0.1% cream on day 1-3 on their whole body, and 
30 g clobetasol propionate on day 4-6 cream on their whole body. On day 1, 3 and 6 the 
morning urine cortisol (nmol/l) was measured. Two other patients with BP received a treatment 
of 20 g clobetasol propionate on 6 consecutive days. On day 1, 3 and 6 the morning urine 
cortisol (nmol/l) was measured.
Statistical analysis
Distributions of survival for disease control, remission and relapse were calculated, the Ka-
plan-Meier method for both disease severity groups, and statistically compared by log-rank test. 
Beforehand the two disease severity groups were compared for age, and dosage of clobetasol 
propionate cream using the rank sum test. Occurrence of itch, urticarial plaques, frequency of 
adverse effects, and the use of other medication were compared by the Fisher exact test. Use 
of other immunosuppressive medication was adjusted by a Cox-model to adjust for suspected a 
priori prognostic significance. For all tests, two-sided p- values of less than 0.05 were considered 
to indicate statistical significance.
Results
Patients
From a cohort of 135 BP patients in the time frame of 11 years, 115 patients were treated 
with whole body potent topical CS. Because of missing data finally 74 patients were eligible 
for further analysis. Of the remaining 74 patients, 40 patients had less than 10 bullae (mild BP) 
and 34 patients had 10 or more bullae (severe BP) initially (Fig 1). Baseline characteristics of the 
patients are shown in table 2. Both groups were comparable for gender (mild group: 27.5% 
males; severe group: 38.2% males) and mean age (mild group: 71.4 years; severe group: 68.2 
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years). The follow up time was 1.5 weeks - 7.5 years (median 38 weeks). In the mild BP group 
(n=40), eight patients were in poor conditions as in dependent of nursing. Fifteen of the 40 
patients had associated neurological disorders like cerebrovascular accident (n=10), multiple 
sclerosis (n=1), parkinson’s disease (n=1) and epilepsy (n=3). In the severe BP group (n=36), 
11 were in poor conditions as in dependent of nursing. Seven of the 36 patients had associated 
neurological disorders like cerebrovascular accident (n=3), multiple sclerosis (n=1), limb girdle 
muscular dystrophy (n=1) and alzheimer’s disease (n=2).
Overall both groups were treated with a comparable dose of clobetasol propionate cream, with 
a mean starting dose of 24.3 g in the mild group and 25.3 g in the severe group, although in 
both groups ranging doses in single patients were used (Table 1) In the severe group, more pa-
tients used adjuvant medication for BP (82.4%) than patients in the mild group (50.0%) (Table 
2) However adjuvant medication was started after disease control when after a relapse potent 
topical CS was not enough to control the disease. Three patients (4.1%) died during potent 
topical CS treatment due to detoriation of the general condition (n=2), and acute lymphoblastic 
leukemia (n=1). The three diseased patients were excluded from the survival analysis of remis-
sion and relapse. 
Disease control, remission and relapse
Control of disease activity was achieved in 36 of the 40 patients with mild BP (90%) and in 25 
of the 34 patients with severe BP (73.6%) (P=0.155) (Fig 2). Four patients in the mild BP group, 
who did not achieve control of disease activity used initially 20g/day clobetasol propionate 
cream (P= 0,708). Of the nine patients in the severe BP group who did not achieve control of 
disease activity, three patients used 20g/day clobetasol propionate cream, three patients used 




Mild BP (40 patients)
< 10 bullae*
31 patients 1 patient 8 patients
Severe BP (36 patients) 
≥ 10 bullae*
19 patients 9 patients 6 patients
Table 1: Initial starting dose of clobetasol propionate cream therapy in single patients. The following protocol was used: first 
month clobetasol propionate cream every day, second month every other day, third month twice a week and fourth month 
once a week. *: the number of blisters seen at the day of first consultation
30g/day clobetasol propionate cream and three patients used 40g/day clobetasol propionate 
cream initially (P= 0,279). The median time to achieve disease control was 20 days. In the 
mild group 64.1% (n=26) reached CR: 35.9% off therapy (n=15) and 28.2% while on ther-
apy (n=11). PR was seen in 15.4% (n=6), whereas 20.5% (n=8) of the patients reached no 
remission. In the severe group 41.2% reached CR (n=14): 5.9% off therapy (n=2) and 35.3% 
on therapy (n=12). PR was reached in 29.4% of the patients (n=10), and 29.4% reached no 
remission (n=20). The different initial doses clobetasol propionate cream a day, PR, CR on and 
off therapy and no remission in every single patient is depicted in figure 1. Complete remission 
was more achieved in the mild BP group (P= 0.025). However no significant difference between 
the two groups exists for reaching any remission (P= 0.278). 
Of those with an initial control of disease, 55.7% experienced a relapse, with 55.6% in the mild 
group and 56.0% in the severe group (P= 0.814). The median time until the occurrence of a 
relapse is 19 weeks, so the relapses occurred mostly after stopping treatment. 
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115 # treated with potent topical steroids
135 # with BP selected from our biobank (2002-2011)
74 # included in this study
41 missing charts







































34 # severe BP
Figure 1: Flowchart of the study. BP: bullous pemphigoid; CR: complete remission; PR: partial remission; NR: no remission.
Local and systemic adverse effects
Overall, 23 adverse effects were reported in 74 patients, 17.5% of the patients in the mild group 
and 29.4% in the severe group experienced one or more adverse effects (P = 0.274) with a 
follow up of 7 years (Table 2).
Main adverse effects in the 74 patients were local like skin atrophy (n=13), purpura (n=4), striae 
(n=2) and xerosis cutis (n=1). Systemic adverse effects were reported in only three patients: deep 
vein thrombosis (n=1), adrenocortical insufficiency (n=1) and hypertrichosis (n=1).
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Figure 2: Clinical features patients treated with potent topical corticosteroid therapy: patient (A) treatment initially with  
20g/day clobetasol propionate cream and result after 1 week; patient (B) treatment initially with 30g/day clobetasol propi-




All BP patients 
(N=74)
Mild BP (N=40) Severe BP (N=34) P value
Male 24 (32.4%) 11 (27.5%) 13 (38.2%) 0,455
Mean Age ± SD 69.9 ± 16.4 71.4 ± 14.4 68.2 ± 18.5 0.402
Mean number of blisters ± SD 18.8 ± 23,2 3.6 ± 3,4 36.7 ± 23,9 0.000
Itch 73 (98.6%) 39 (97.5%) 34 (100%) 1.000
Urticaria 21 (28.4%) 6 (15.0%) 15 (44.1%) 0.009
Mean begin doses clobetasol (g) ± SD 24.7 ± 8.0 24.3 ± 8.1 25.3 ± 7.9 0.578
Use of other medication 48 (64.9%) 20 (50.0%) 28 (82.4%) 0.007
azathioprine 6 (8.1%) 4 (10.0%) 2 (5.9%)
doxycycline, nicotinamide 11 (14.9%) 7 (17.5%) 4 (11.8%)
prednisolone 11 (14.9%) 4 (10.0%) 7 (20.6%)
methotrexate 1 (1.4%) 1 (2.5%) 0 (0%)
azathioprine, prednisolone 13 (17.6%) 2 (5.0%) 11 (32.8%)
doxycycline, nicotinamide, prednisolone 5 (6.8%) 2 (5.0%) 3 (8.8%)
azathioprine, doxycycline, nicotinamide, 
prednisolone
1 (1.4%) 0 (0%) 1 (2.9%)










atrophy 13 6 7
purpura 4 2 2
striae 2 0 2
xerosis 1 0 1
deep vein thrombosis 1 0 1
adrenocortical insufficiency 1 0 1
hypertrichosis 1 0 1
Table 2: Patient characteristics.
Systemic effect
A decrease in number of eosinophils was seen in nine patients after the application of clobetasol 
propionate cream. This effect was already observed after one day of the start of treatment. 
Eosinophil number dropped to normal range (0.0-0.40 10^9/L) after an average of 5.6 days 
(Fig 3).
In one patient morning urine cortisol did not drop after three days of 30 g triamcinolon aceto-
nate 0.1% cream applied on the whole body. In contrast, after 30 g clobetasol propionate cream 
on the same area, morning urine cortisol dropped to 5.0 nmol/L (Fig 4). This patient did not use 
any other medication. A second patient applied 20 g clobetasol propionate cream on the whole 
body for 6 consecutive days. Morning urine cortisol dropped to 2.0 nmol/L. A third patient 
applied 20 g clobetasol propionate cream on the whole body for 6 consecutive days. Morning 
urine cortisol dropped from 14.4 nmol/L (day 1) to 3.4 nmol/L (day 6). Both patients did not 
use any other medication. These results demonstrate systemic effects of whole body potent CS 
application. 
Pharmaco-economics 
In the Netherlands the costs of 100 gram clobetasol propionate cream are €11.50 ($14.77). 
For a patient treated with the 20g/day clobetasol propionate cream protocol the costs for the 





























Figure 3: Number of eosinophils after treatment with potent topical corticosteroid therapy
treatment of one patient with potent topical CS during 4 months will be €124.20 ($159.56) 
and for patients treated with 30g/day €174.80 ($224.57). The costs of prednisolone (20 mg) is 
€0.14 ($0.18), osteoporosis prophylaxis costs €0.38 ($0.49) per day, and antacids costs €0.02 
($0.03) per day. A mild BP patient will be treated with 20 gram prednisolone per day tapered in 
3 months in combination with osteoporosis prophylaxis and antacids. Total cost will be approxi-
mate €40.46 ($52.30)
A severe BP patient will be treated with 40 gram prednisolone per day tapered in 3 months in 
combination with osteoporosis prophylaxis and antacids. Total cost will be approximate €47.46 
($61.35)
Discussion
Treatment of BP is challenging because of the older age of the patients and their associated 
comorbidities. Joly et al. reported that topical application of clobetasol propionate cream on the 
whole body has a similar efficacy in severe BP as oral CS with disease control within 12 months 
of >98%, at the cost of much lower morbidity and mortality (50% reduction).6,10 In our study 
we show a high disease control (90%) in mild BP after four months with topical potent CS close 
to that previously reported.10 The rate of disease control in severe BP was lower (73.6%) than 


























/l Day 1,2,3: triamcinolone 0.1% cream
Day 4,5,6: clobetasol propionate cream
Figure 4: Morning urine cortisol measurement. Day 1-3: whole body application of 30 g triamcinolon acetonate 0.1% 
cream. Day 4-6 whole body application of 30 g clobetasol propionate cream.
the study by Joly et al. (from 30-40g/day).10 Our results confirm that whole body application of 
clobetasol propionate as monotherapy is sufficient to control disease in mild BP and in severe BP. 
The overall occurrence of a relapse was similar compared with the study of Joly et al. in mild BP 
(56% versus 43%), and in severe BP (56 % versus 35%) using the four months regimen. These 
relapse rates compares favorably with relapse rates obtained with systemic CS (60 to 80%).6,10 
Because these relapses were mainly observed after stopping treatment at four months, adjuvant 
maintenance therapy may be useful to keep the disease in remission after the induction phase 
with clobetasol. We prefer azathioprine in 2-3 mg/kg/day dosage. Other adjuvant options 
are methotrexate, dapsone, mycophenolate mofetil, mycophenolic acid, cyclophosphamide, 
intravenous immunoglobuline and rituximab. Recently the “Groupe Bulle” reported that the 
combination of initial short-term potent topical steroids (clobetasol propionate and bethametha-
sone propionate) with low-dose methotrexate resulted in an even better result.11 
Tolerance of treatment is a crucial point in fragile, especially in elderly BP patients with signifi-
cant, often numerous comorbidities and associated neurological disorders. In the French studies 
side effects were observed in 29% of patients treated with clobetasol propionate cream, while 
in our series this was 23%. The experienced side effects were related to clobetasol treatment 
and mostly local such as skin atrophy or purpura, and did not require treatment discontinuation. 
Systemic adverse effects were only seen in three patients with severe BP (hypertrichosis, deep 
vein thrombosis, adrenocortical insufficiency) and none were observed in mild BP. This low 
percentage of systemic adverse events demonstrates the safety of topical whole body CS.  
Furthermore it is important to have attention for the pharmaco-economics. In regard to med-
ication costs, application of topical CS is three times more expensive compared to treatment 
with oral CS in BP, although the treatment is cheap and do does not extend above €175 in 4 
months. The costs for whole body application by home care nurses were not accounted for, and 
substantially increase the total costs. Moreover, lubricating the whole body can be stressful for 
elderly patients. However, the costs due to more adverse systemic events by oral CS may push 
the financial balance back in favour of topical CS. 
The whole body application of clobetasol propionate cream has local and systemic effects 
witnessed by the drop in morning urine cortisol and eosinophil count. In these patients no 
systemic side effects were seen. A validated assay for percutaneous absorption of clobetasol was 
not available in our study period and became available in 2010 by Van Velsen et al.12 The same 
authors have showed the systemic absorption and effects of whole body application of clo-
betasol propionate 0.05% cream in patients with atopic dermatitis. A single application resulted 
in detectable serum levels of clobetasol propionate of 0.112-4.504 ng/ml, and decreased 
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cortisol levels, from 0.47 ± 0.18 μmol/l to 0.04 ± 0.05 μmol/l after 1 day.13 Moreover the same 
whole body application of a less potent topical CS (betamethason valerate) did show in a few 
patients systemic absorption and fluticasone propionate cream application did not show systemic 
absorption.
More studies are needed to evaluate the systemic effects and the serum levels of clobetasol pro-
pionate after whole body topical clobetasol application in BP patients. Limitations of our study 
are in first place the differences in starting dose of clobetasol propionate cream in single patients. 
Furthermore some patients received also immunosuppressants, although these medications in all 
cases were started after the fourth month regimen when a patient received a relapse. Secondly 
we have a high lost of patients (n=41) because of missing data. These limitations can impair the 
results of our study.
In conclusion we found that whole body application of clobetasol propionate cream is effective 
in the induction phase of treatment in patients with mild BP and in patients with severe BP. We 
advice to add an immunosuppressive drug in BP patients with a relapse when topical clobetasol 
propionate cream is not sufficient anymore. The whole body clobetasol therapy is safe and may 
be better tolerated than systemic oral CS. 93
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General discussion and future perspectives 
Fully awareness of new insights of techniques, clinical symptoms and treatment options in 
pemphigoid diseases is mandatory to be leading in the field. In this thesis we focussed on these 
three pillars.
In the last decade the incidence in pemphigoid diseases has increased substantially. BP shows a 
rising incidence two to five times rising to 13.4-21.7 per one million people.1 Bullous pemphigoid 
(BP) is a disease of the elderly, and because there is aging of the worldwide population more 
BP will be diagnosed in the future. However in Finland the age-adjusted incidence of BP was 
also increased remarkably.2 The use of multiple drugs in older patients could be an explanation 
of this rising incidence. Loyd-Lavery et al. reported recently an increased use of loop diuretics 
in patients with BP before the development of BP, confirming the relation between BP and use 
of medication.3 The Netherlands Consortium for Healthy Ageing (NCHA) provides us many 
different options of research and includes LifeLines which is a scientific study and biobank, 
where during thirty years 165.000 residents of the Northern Netherlands are being followed. 
The hypothesis that the rising incidence of BP might be due to the use of multiple drugs needs 
support by further research such as longterm follow-up in large cohorts as LifeLines.
Direct immunofluorescence (DIF) is because of the high sensitivity the gold standard in the 
diagnostic approach of pemphigoid diseases. There was still lack of use of the serration pattern 
analysis by DIF. The image-based online test and instruction video (www.nversusu.umcg.nl) 
we developed and presented in chapter 2 was unique and will spread the knowledge of the ser-
ration pattern analysis. The test and instruction video will be updated frequently, so participants 
are triggered to enhance their experience. The test was suitable for every participant, despite 
the level of experience, and improvement of DIF serration pattern analysis after instruction 
was shown. Notable was the better recognition of the u-serrated pattern compared with the 
n-serrated pattern. With the increased knowledge of serration pattern analysis by DIF, more 
accurate diagnoses can be made in pemphigoid diseases. The actual incidence of epidermolysis 
bullosa acquisita (EBA) is 0.2-0.5 new case per million people per year.4 When serration pattern 
analysis is routinely performed more EBA patients will be diagnosed. Schmidt et al. reported 
that only 40–60% of EBA serum samples reacted by indirect immunofluorescence microscopy 
on salt-split skin (SSS) showing dermal binding of the artificial blister, concluding that many EBA 
patients are underdiagnosed when serration pattern analysis by DIF is lacking.5 We described 
that 40% of our EBA serum samples react by indirect immunofluorescence microscopy on salt-
split skin (SSS), showing dermal binding. In 45% of our EBA serum samples the NC1/NC2 ELISA 
is positive. When we combine those two assays we diagnose in 50% of our serum samples EBA. 
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Without performing DIF serration pattern analysis we miss about 50% of the EBA cases. We 
demonstrated in 93% of our EBA population the u-serrated pattern by DIF. Another advantage 
of the serration pattern analysis is the possibility to distinguish the inflammatory EBA from other 
pemphigoid diseases like BP, mucous membrane pemphigoid (MMP), anti-p200 pemphigoid 
or linear IgA bullous dermatosis (LAD). Subtyping in pemphigoid diseases is important because 
of the different prognosis, complications and treatment of the disease. No controlled prospec-
tive trials have been reported in the treatment of EBA. In general, treatment is unsatisfactory, 
especially in the mechanobullous phenotype. A larger EBA population gives the opportunity to 
conduct randomized controlled trials in the future and treatment in EBA can be optimalized.
Besides DIF, serological analysis was of added value in the diagnostic approach of pemphigoid 
diseases. Traditionally indirect immunofluorescence (IIF) and IIF on SSS are two valuable assays 
to detect circulating autoantibodies. Identification of specific autoantigens was not possible with 
these tests. Immunoblot (IB), enzyme-linked immunosorbent assay (ELISA), immunoprecipitation 
(IP), knock-out immunofluorescence analysis (KO) and fluorescent overlay antigen mapping 
(FOAM) are further specifying assays, each with their benefits and disadvantages. Recently 
commercially available ELISA’s for type VII collagen (C7) have emerged, that consists of recom-
binant NC1 and NC2 C7 domains coated to the plate. In chapter 3 we confirm the promising 
use of this ELISA in monitoring disease activity in EBA patients. However the high sensitivity 
(>93%)  and specificity (>96%) described by Saleh et al. and Kim et al. of this ELISA is not 
based on daily routine, because only SSS positive patients were included in their studies.6,7 In our 
study we included SSS positive and SSS negative EBA patients, avoiding selection bias, and show 
a much lower sensitivity (45%). The use of the C7 ELISA is an investigative contribution, though 
DIF for serration pattern analysis on skin biopy when suspecting EBA is still mandatory. The C7 
ELISA has proven its use in monitoring disease activity in patients.6,7 This ELISA will be used more 
frequently in the future for monitoring disease activity when tapering treatment. The anti-C7 
ELISA kit containing the recombinant NC1 and NC2 domains (MBL, Nagoya, Japan) would be of 
great use in IgA EBA patients but does not confirm to current criteria. Monitoring disease activity 
in this group is desirable and future development of an accurate IgA C7 ELISA might be of great 
use in a clinical setting.
For the serological diagnosis of pemphigoid diseases multiple techniques like IB, ELISA, IP, KO 
and FOAM can be used. This is expensive and labor-intensive. Using multiple substrates, includ-
ing antigen specific substrates, in a single test one can be costs and labor sufficient. Van Beek 
et al. developed a multiplex IF BIOCHIP mosaic that combined screening and target antigen 
specific substrates for pemphigus and pemphigoid showing a high sensitivity and specificity.8 
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Zarian et al. used the BIOCHIP in the detection of BP180 autoantibodies in BP patients, de-
scribing almost the same diagnostic specificity compared to the NC16A ELISA. The anti-BP230 
globular C-terminal domain diagnostic sensitivity was slightly reduced.9 The multiplex IF 
BIOCHIP is a new assay which is easy to use, and sensitivity and specificity in current studies are 
promising. A disadvantage is that it cannot be used as a quantitative measure. Further research 
and enlargement of the BIOCHIP with envoplakin and rat bladder will give more insights in the 
specific role of this interesting assay in diagnostics of pemphigoid diseases.
Anti-laminin-332 MMP (Anti-LN-332 MMP) is a rare subtype of pemphigoid that in first in-
stance is difficult to distinguish from other forms of MMP. It is known for the scarring phenotype 
with airway obstruction due to pharyngeal and laryngeal involvement or lost of vision because 
of subconjunctival fibrosis and cicatrization.10 Furthermore patients have an increased relative 
risk for malignancy, especially adenocarcinoma.11,12 Because of this clinical aggressive behavior 
it is important to diagnose patients in an early phase of the disease. Because of new insights 
presented in chapter 4 we have described additional major and minor criteria to diagnose 
anti-LN-332 MMP. The major criteria consists of: (i) subepithelial erosions or blisters on mucous 
membranes frequently associated with scarring phenotype, (ii) depositions along the BMZ in an 
n-serrated pattern by DIF, (iii) IgG bound to the dermal side of 1-mol/L NaCL-split human skin 
by IIF. The minor criteria comprise: (i) anti-LN α3, β3, or γ2 IgG binding by immunoblot analysis 
on keratinocyte cell extract, (ii) IgG reactivity to native LN-332 by ELISA, (iii) serum immunopre-
cipitation of LN-332 trimer, (iv) negative IIF on LN-332 deficient skin, while positive IIF on C7 
deficient skin, (v) IgG BMZ deposits overlay LN-332 by FOAM. To diagnose anti-LN-332 MMP 
at least three major criteria, or two major criteria and one minor criterion must be obtained. 
When these criteria are used adequately, anti-LN-332 MMP will be diagnosed in the early phase 
of the disease, avoiding serious complications because of doctors delay. Accurate treatment 
can be introduced and thoroughly screening for malignancies will be performed. An important 
pitfall is the distinction between anti-LN-332 MMP and anti-p200 pemphigoid. Both diseases 
show the n-serrated pattern by DIF and dermal binding in SSS. Clinically anti-LN-332 MMP 
can be distinguished from anti-p200 pemphigoid by dominant mucosal lesions, the oral mucosa 
and eyes are affected mostly. Anti-p200 pemphigoid presents clinically heterogeneous with 
tense blisters and urticaria, mimicking BP.5 According to our new criteria for anti-LN-332 MMP 
another minor criteria must be obtained when clinical presentation is not according the classical 
anti-LN-332 MMP phenotype. There is a subset of patients with no confirmative serological 
test for anti-LN-332 MMP and interestingly with a knock-out analysis showing positive IIF on 
LN-332 deficient skin, and positive IIF on C7 deficient skin. The use of immunblot or ELISA 
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showing reactivity with the laminin γ1 epitope could be the answer for the missing link. To date, 
the pathogenic autoantigen involved in anti-p200 pemphigoid was not revealed. Dainachi et al. 
performed 2-D gel electrophoresis of dermal extracts and immunoblotting with patients’ sera, 
followed by mass spectrometry analysis of a unique protein band. In 90% of their anti-p200 sera 
from 32 patients reactivity to the recombinant products of laminin γ1 was seen, suggesting that 
the C-terminus of laminin γ1 was the autoantigen in anti-p200 pemphigoid. They renamed the 
disease in anti-laminin γ1 pemphigoid.13 In 2012 Vafia et al. employed an ex vivo model and 
showed that autoantibodies in anti-p200 pemphigoid sera are pathogenic while pathogenicity is 
not mediated by autoantibodies against laminin γ1.14 The intriguing question is which auto-
antigen is pathogenic in anti-p200 pemphigoid and how to subtype and name these patients. 
Further research has to be performed to answer this antigen gap in the pemphigoid diseases 
spectrum.
In chapter 5 we described 15 patients with pruritus, immunopathological findings of BP but 
no blister development. We proposed the unifying term ‘pruritic nonbullous pemphigoid’, in 
the spectrum of BP for all patients with immunopathological findings of BP, itch and no blisters, 
to trigger the dermatologist to think of pemphigoid when confronted with an elderly who 
complains of itch. We were the first to describe patients (3/15) that only had pruritus without 
primary skin lesions (pruritus sine materia or ‘itch without rash’) but immunopathological 
findings of BP. This observation is of utmost important in the diagnostic algorithm for elderly 
patients with pruritus in the future. To diagnose ‘pruritic nonbullous pemphigoid’ preferably DIF 
must be positive or otherwise SSS positive in combination with another confirmative serological 
test like Western immunoblot or ELISA. One must be aware that patients with single positive 
results on NC16A or BP230 ELISA must not be considered as having BP or a BP variant. Feliciani 
et al. investigated IgG reactivity against the autoantigens of BP, BP180 and BP230, by ELISA in 
sera of 15 patients with pruritic disorders, without blister development. In 33% of these sera 
IgG against BP230 and/or BP180 was reported. This confirms the hypothesis that IgG reactivity 
against BP230, and to a lesser extent against BP180, is a common finding in pruritic disorders of 
the elderly with a wide clinical spectrum. The relevance of these autoantibodies in patients with-
out clinical symptoms of BP was not cleared. More studies are needed to clarify if these solitary 
NC16A and BP230 autoantibodies serve as clinical markers in the absence of BP or represent an 
insignificant epiphenomenon. IgG is the predominant autoantibody in BP patients; however the 
role of IgE autoantibodies has also been reported before in BP to be pathogenic.15,16 This insight 
is of interest for pruritic nonbullous pemphigoid patients. When histological examination of a BP 
patient is performed a dermal inflammatory infiltrate with eosinophylic spongiosis consisting of 
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dermal edema associated with eosinophylic infiltration of the upper dermis is frequently seen.17 
Elderly individuals with pruritic dermatosis present often with elevated IgE serum levels. These 
elevated serum levels were also described in up to 70% of the BP patients. In this same report 
Dimson et al. showed that in 31 of 32 patients the IgE was bound to the pathogenetic NC16A 
domain of BP180.18 This observation led to further research and Zone et al. produced histological 
blisters of the BMZ in SCID mice after injection subcutaneously an IgE hybridoma to the BP180 
ectodomain (LABD97 antigen).19 Fairley et al. demonstrated that after injecting 6 ng of total IgE 
isolated from two BP and two normal sera into human skin grafted onto athymic, nude mice 
revealed the prodromal lesions of BP. After injecting a higher dose of BP IgE (47 ng), histological 
cleavage of the BMZ was observed in two of the three grafts.16 These observations suggest 
a critical role of IgE autoantibodies in the pathogenesis of BP and may be a marker for the 
intensity of the pruritic symptoms. In the near future sera of our pruritic nonbullous  
pemphigoid patients will be investigated by IgE NC16A ELISA. To date, only few reports showed 
IgE depositions along the epidermal basement membrane zone by DIF on patient skin biop-
sies,20-22 and future research must be address this issue. Targeted therapy in patients with pruritic 
BP, high levels of IgE and eosinophils is also of interest. Omaluzimab, a humanized anti-IgE 
antibody, is used in daily practice in patients with moderate to severe persistent allergic asthma 
caused by year-round allergens in the air. In vitro experiments have shown that omalizumab is 
able to induce eosinophil apoptosis and downregulation of pro-inﬂammatory cytokines syn-
thesized by T- lymphocytes.23 Recent reports in selected cases show successful treatment with 
omaluzimab of patients with pruritic BP and elevated IgE levels.24,25 The efficacy of omaluzimab 
in patients with BP without high levels of IgE and eosinophils is not known. Future research must 
be address this issue and might reveal a new promising therapy in pemphigoid diseases. Further-
more, from a pathogenic view, it might be interesting to dissolve the mechanisms behind the 
absence of blister formation in nonbullous pemphigoid.26-29 Complement activation has been said 
to play an important role in the formation of blisters in BP. Therefore, bullous and nonbullous 
pemphigoid might differ in the way of complement activation. In this respect it is challenging to 
hypothesize that in nonbullous pemphigoid the IgG antibodies might predominantly be of the 
IgG4 subclass which has restricted Fc activating abilities and does not activate C1q.30
Treatment of BP is challenging because patients are mainly elderly and have comorbidities like 
neurological and cardiovascular disorders that are associated with the age and the disease.31 
These patients use often multiple drugs and are at high risk of adverse drug reactions and 
side-effects. In 2010 a Cochrane review was published summarizing the reports for treatment of 
BP, and concluded that potent topical corticosteroids (CS) are effective and safe, although the 
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use may be limited because of side effects and practical issues. Systemic oral CS with an initial 
dose of 0.5-0.75 mg/dag is the best established treatment according to current evidence but 
iatrogenic morbidity and mortality is reported.32,33 In chapter 6 we describe that whole body 
application of clobetasol propionate cream is effective in the induction phase of treatment in 
patients with mild BP and in patients with severe BP. The high efficacy of whole body topical 
clobetasol propionate application is in our opinion due to both local and systemic effects. We 
confirmed this hypothesis by showing the drop in morning urine cortisol and eosinophil count in 
patients treated with clobetasol propionate cream on their whole body, sparing the face. Despite 
of this systemic effect we found in only three patients systemic adverse effects (hypertrichosis, 
deep vein thrombosis, adrenocortical insufficiency) demonstrating the safety of topical whole 
body CS. An important question to be asked is with what dose of oral CS the topical potent CS 
on the whole body therapy can be compared. Van Velsen et al. reported the systemic absorption 
and effects of whole body application of clobetasol propionate 0.05% cream in patients with 
atopic dermatitis. Serum concentrations of clobetasol propionate can be measured by liquid 
chromatography-tandem mass spectrometry (LC/MS/MS).34 A single skin application resulted 
in detectable serum levels of clobetasol propionate of 0.112-4.504 ng/ml, and decreased 
cortisol levels, from 0.47 ± 0.18 μmol/l to 0.04 ± 0.05 μmol/l after 1 day. Moreover the same 
whole body application of a less potent topical CS (bethamethason valerate) showed in a few 
patients systemic absorption and fluticasone propionate cream application did not show systemic 
absorption.35 
The biological half-life of clobetasol propionate cream is unknown. Hehir et al. reported that 
cortisol levels remain low until 96 hours after a single application of 25g clobetasol propionate 
in patients with eczema or psoriasis. Watson et al. showed that cortisol levels were normal 24 
hours after a single orally administered dose of 25 mg prednisolone in healthy volunteers. This 
suggests that the biological half-life of clobetasol propionate cream is longer than the biological 
half-life of prednisolone. Furthermore this assumes that 20-30 g clobetasol propionate cream is 
equipotent to 25-40 mg prednisolone by oral administration. Future research must be performed 
to analyze the systemic effect, the differences and similarities of topical potent CS on the whole 
body therapy compared to oral CS in the treatment of BP. Rituximab (MabTheraTM; Roche, 
Basel, Switzerland) is a chimeric human–mouse monoclonal antibody, which binds specifically 
to the transmembrane antigen CD20 expressed on B-lymphocytes from the pre-B-cell stage to 
the pre-plasma-cell. Treatment with rituximab shows promising result in patient with pemphigus 
vulgaris although in pemphigoid diseases literature is limited and rituximab is used frequently as 
third-line treatment option of recalcitrant BP, MMP, or EBA. Recently Shetty et al. published a  
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review of the literature of 20 MMP patients who were treated with rituximab using the lym-
phoma protocol which involves a dose of 375 mg/m2 administered weekly for 4 consecutive 
weeks showing that rituximab benefits patient with MMP. Many limitations were addressed in 
this review, for example the use of concomitant therapy with immunosuppressive and anti-
inflammatory agents in 19/20 patients, and long-term follow-up, studies on B-cell levels and 
antibody responses are lacking.36 In our Centre for Blistering Diseases we used rituximab in 11 
patients with different subtypes of recalcitrant pemphigoid diseases (n=3 BP, n=2 MMP, n=2 EBA 
mechanobullous phenotype, n=1 OCP, n=1 CP, n=1 IgA-EBA and n=1 LAD). In this group three 
patients had complete remission (BP, MMP, EBA mechanobullous phenotype), five patients had 
partial remission (two BP, 1 EBA mechanobullous phenotype, 1 MMP and 1 OCP), and three 
patients had no response (IgA EBA, LAD and CP). Future research should focus on the efficacy 
and long-term follow-up of the use of rituximab or other forthcoming anti-CD20 monoclonal 
antibodies to find their place in the therapeutic armamentarium of pemphigoid diseases.
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Pemphigoid diseases is a group of subepidermal autoimmune blistering diseases (sAIBD) 
characterized by circulating autoantibodies targeting structural proteins that link the cytoskeleton 
of the basal keratinocytes to the to the underlying epidermal basement membrane zone (BMZ). 
Binding of the autoantibodies leads to separation of the epidermis and dermis resulting clinically 
in tense blisters and erosions. Pemphigoid diseases can be divided into different subtypes like 
bullous pemphigoid (BP), mucous membrane pemphigoid (MMP), ocular cicatricial pemphigoid 
(OCP), anti-laminin-332 MMP (anti-LN-332 MMP), anti-p200 pemphigoid, anti-plectin  
pemphigoid, linear IgA dermatosis (LAD), pemphigoid gestationis (PG), lichen planus pemphi-
goïdes (LPP), Brunsting-Perry pemphigoid and epidermolysis bullosa acquisita (EBA). 
The 180-kD antigen (BP180, BPAG2, or type XVII collagen), and the 230-kD antigen (BP230, 
BPAG1) are the main target antigens in BP, MMP, LAD, PG, OCP, Brunsting-Perry pemphigoid 
and LPP. LN-332 is the target antigen in anti-LN-332 MMP. EBA patients show circulating auto-
antibodies targeting collagen VII (coll VII). Anti-p200 pemphigoid  is characterized by circulating 
autoantibodies against the 200 kDa-protein of the lower lamina lucida.
The different subtypes of pemphigoid diseases share clinical characteristics such as tense blisters 
and erosions although every subtype has its own overall clinical presentation, target antigens, 
circulating specific autoantibody isotype, treatment and prognosis.
In this thesis we present an overview of pemphigoid diseases with the correlating clinical criteria, 
optimize the use and interpretation of direct immunofluorescence (DIF), indirect immunoflu-
orescence (IIF), and immunohistochemical assays, and we specify “tailor made” treatment in 
pemphigoid diseases.
In 2004, our Centre for Blistering Diseases described the serration pattern analysis by routine DIF 
showing linear n-serration or linear u-serration immunodepositions along the BMZ. The u-serra-
tion pattern confirms the diagnosis EBA and represents immunoglobulin depositions in upstand-
ing arms (“grass”) of the sublamina densa zone between the rootlets of basal keratinocytes. In 
all other sAIBDs the antigens are located in the lamina lucida or above, so the immunodeposits 
follow the rootlets of the basal keratinocytes showing the n-serration pattern. However since 
its first publication, DIF serration pattern analysis has found limited use, although the criterion 
is mentioned in textbooks and in the forthcoming European guideline on AIBD. The limited use 
might be caused by uncertainty and lack of training of the IF microscopists. In chapter 2 we 
tested the learnability of DIF serrated pattern recognition under groups with various a priori 
levels of competence. An online nversusu-test (www.nversusu.umcg.nl) was created, which 
contained 26 DIF images of BMZ, IgG stained, and photographed with a magnification of 40x 
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and 63x. All images represented patients with a form of pemphigoid diseases. Thirteen DIF 
images were presented before and thirteen DIF images after an instruction video about n- and 
u-serrated patterns. There were three options to choose from: n-serrated, u-serrated or unde-
termined. The test was completed by three groups of professionals: i) dermatology residents in 
training at the University Medical Centre Groningen, ii) International experts on bullous diseases, 
iii) dermatologists and pathologists who participated in the Groningen Blistering Course in the 
last 10 years. Overall the number of correct answers of serration patterns was significantly 
higher after instruction than before instruction (median 9.0 correct answers vs. 11.0 correct 
answers, P<.001). Participants showed a mean improvement after instruction of 15.4% in the 
UMCG group (66.7% vs. 82.1%), 16.2% in the International expert group (67.2% vs. 83.4%) 
and 12.1% in the Blistering Course group (60.7% vs. 72.8%). The u-serrated pattern was better 
recognized than the n-serrated. We concluded that serration pattern analysis by DIF can be 
learned irrespective of background of expertise.
Recently new ELISA’s for the detection of autoantibodies against coll VII have emerged for 
diagnosing EBA patients. A commercial ELISA is available that has the recombinant NC1 and 
NC2 coll VII domains coated to the plate, and high sensitivity (>93%) and specificity (>96%) 
has been reported. A correlation between coll VII ELISA index and disease severity was also 
demonstrated. All these studies relied on sera that were positive by salt split skin analysis (SSS). 
In chapter 3 we investigated how the type VII coll ELISA would contribute to diagnose EBA in 
a normal routine setting. We performed type VII coll ELISA on banked sera of 28 EBA patients: 
15 SSS-positive and 13 SSS-negative. Sera from healthy blood donors (n=17) and other autoim-
mune blistering diseases (n=29) served as controls. In four patients ELISA index was measured 
longitudinally. Serration pattern analysis by DIF was prospectively performed since 2000 and 
comprised 19 patients. The sensitivity in the SSS-positive group was 80% whereas it was 23% in 
the SSS-negative group. In the prospective EBA subset it was 45%. The sensitivity of u-serration 
pattern analysis on skin biopsy was 89%. Ten (53%) of these cases were seronegative by both 
ELISA and SSS, and would have been missed by serum analysis alone. Of the 46 control sera 
one serum tested positive (specificity 97.8%). The coll VII ELISA correlated with disease activity 
over time in individual patients. With these results we show that coll VII ELISA has limited added 
value in SSS-negative EBA cases. The ELISA test is very valuable in differentiating EBA from 
anti-laminin-332 MMP and anti-p200 pemphigoid and in its ability to serological monitor EBA 
patients. We state that u-serration pattern analysis on IF skin biopsy remains the gold standard 
for the diagnosis of EBA.
Anti-LN-332 MMP is a subtype of pemphigoid diseases characterized by IgG autoantibodies 
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against LN-332. Anti-LN-332 MMP can clinically resemble other forms of pemphigoid. For 
diagnosis of anti-LN-332 MMP difficult to obtain laboratory techniques are needed. A correct 
diagnosis is important because patients with anti-LN-332 MMP have an increased relative risk 
of malignancy and should be thoroughly oncologically screened. In chapter 4 we described the 
clinical features and immunopathological findings in a cohort of 10 Dutch patients. New insights, 
as described in this chapter, leads to additional criteria to diagnose anti-LN-332 MMP. We pre-
sented the following major and minor criteria. Major criteria: 1) Subepithelial erosions or blisters 
on mucous membranes frequently associated with scarring phenotype, 2) IgG depositions along 
the BMZ in the n-serrated pattern by DIF, 3) IgG bound to the dermal side of 1-mol/L NaCL-split 
human skin by IIF. Minor criteria: 1) Anti-LN α3, β3, or γ2 IgG binding by immunoblot analysis 
on keratinocyte cell extract , 2) IgG reactivity to native LN-332 by ELISA, 3) Serum immuno-
precipitation of LN-332 trimer, 4) Negative IIF on LN-332 deficient skin, while positive IIF on 
type VII collagen deficient skin, 5) IgG BMZ deposits overlay LN-332 by fluorescence overlay 
antigen mapping (FOAM). To diagnose anti-LN-332 MMP at least three major criteria, or two 
major criteria and one minor criterion must be obtained. The combination of simple DIF serration 
pattern and IIF SSS analysis will exclude other forms of MMP and epidermolysis bullosa acquisita 
from the differential diagnosis.
BP is the most common subtype of pemphigoid diseases and frequently affects elderly and the 
associated morbidity is significant. In the recent “Definitions and outcome measures for bullous 
pemphigoid” pruritus, urticaria and tense blisters were reported as the three main clinical pillars 
of BP. Confusing is the subset of patients with immunopathological findings of BP, pruritus, 
but no blister development for years. In the literature there is no consensus on how to name 
this subset of patients. The coined terms include ‘pruritic pemphigoid’, ‘pemphigoid nodularis’, 
‘papular pemphigoid’, ‘prurigo-nodularis like pemphigoid’, ‘nonbullous BP’, ‘prodromal BP’, 
‘cutaneous pemphigoid’ and ‘BP incipiens’. In chapter 5 we presented fifteen patients with 
immunopathological findings of BP who had pruritus sine materia or pruriginous skin lesions 
without blisters.  Diagnosis was reached by a positive DIF with IgG and/or C3c along the 
epidermal BMZ, or SSS-epidermal binding in combination with a positive ELISA (NC16A or 
BP230). Clinical symptoms were heterogeneous: pruritus sine materia (no primary skin lesions), 
eczematous, urticarial, papular and/or nodular skin lesions were seen. Treatment with potent 
topical corticosteroids or methotrexate sodium (5-15mg/week) led to remission in eleven pa-
tients. To trigger the dermatologist to think of pemphigoid when confronted with an elderly who 
complains of itch we proposed the unifying term ‘pruritic nonbullous pemphigoid’. We state that 
when an elderly with therapeutic refractory itch is presented in the clinic, DIF and IIF must be 
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performed to exclude pruritic nonbullous pemphigoid.
Treatment of BP is challenging because of the older age of the patients, and the comorbidities 
like neurological and cardiovascular disorders that are associated with the age and the disease. 
Current standard of treatment of BP is systemic oral corticosteroids (CS). However significant 
iatrogenic morbidity and mortality is reported. Studies have shown that topical potent CS is 
safer than oral prednisolone in BP. In chapter 6 we examined the efficacy and adverse effects 
of whole body topical clobetasol propionate cream application in patients with mild or severe 
BP. Moreover we investigated cortisol levels and eosinophil counts in selected cases and found 
systemic effects using a potent topical CS. We performed a retrospective analysis of a series of 
mild (n=40) and severe (n=34) BP patients, treated with ranging doses (20-40g/day) clobetasol 
propionate cream. For assessing systemic effects we observed in selected cases eosinophil count 
and morning urine cortisol level. Patients with mild BP achieved in 90.0% disease control and in 
severe BP in 73.5%. Complete remission was achieved in mild BP in 64.1% (35.9% off therapy 
and 28.2% on therapy) versus 41.2% in severe BP (5.9% off therapy and 35.3% on therapy). 
Local adverse effects were mainly skin atrophy (14.9%) and purpura (5.4%). Systemic adverse 
effects were rare (n=3) and consisted of deep vein thrombosis, hypertrichosis and adrenocor-
tical insufficiency. Systemic effect was witnessed by immediate drop of eosinophil count, and 
decrease in the morning urine cortisol in selected cases. These results show that whole body 
application of clobetasol propionate cream is effective in the induction phase of treatment in pa-
tients with mild BP and in patients with severe BP. We advice to add an immunosuppressive drug 
in BP patients with a relapse when topical clobetasol propionate cream is not sufficient anymore. 
The whole body clobetasol therapy is safe and may be better tolerated than systemic oral CS. 
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Pemfigoïd is een heterogene groep subepidermale autoimmuun blaarziekten (sAIBD) geken-
merkt door circulerende autoantistoffen gericht tegen eiwitten in de epidermale basaalmem-
braan zone (BMZ). De epitheelcellen van de huid zijn via de hemidesmosomen (HD’s) verbonden 
met de onderliggende dermale matrix en defecten in deze adhesiecomplexen zorgen voor 
fragiliteit en blaarvorming van de huid en slijmvliezen. In het het pemfigoïd spectrum zijn vele 
subtypen te onderscheiden zoals: bulleus pemfigoïd (BP), slijmvlies pemfigoïd/mucosaal mem-
braneus pemfigoïd (MMP), oculair cicatricieel pemfigoïd (OCP), anti-laminine-332 slijmvlies 
pemfigoïd (anti-LN-332 MMP), anti-p200 pemfigoïd, anti-plectine pemfigoïd, lineaire IgA 
dermatose (LAD), pemfigoïd gestationis (PG), lichen planus pemphigoïdes (LPP), Brunsting-Perry 
pemfigoïd en epidermolysis bullosa acquisita (EBA). Het 180-kD antigeen (BP180, BPAG2 
of type XVII collageen) en het 230-kD antigen (BP230, BPAG1) zijn de belangrijkste target 
antigenen bij BP, MMP, LAD, PG, OCP, Brunsting-Perry pemfigoïd en LPP. Bij anti-LN-332 
MMP zijn de circulerende autoantilichamen gericht tegen LN-332 en bij EBA tegen collageen 
VII (coll VII). Anti-p200 pemfigoïd is een zeldzame vorm van pemfigoïd waarbij autoantistoffen 
tegen het 200-kDa eiwit van de lamina lucida worden aangetoond. Er zijn enkele klinische 
overeenkomsten tussen de verschillende subtypen zoals pral gespannen blaren, erosies en, zoals 
in tegenstelling tot bij pemphigus, een negatief teken van Nikolsky. Echter er zijn ook unieke 
verschillen qua klinische symptomen, target antigenen, antilichaam subtype, behandeling en 
prognose te definiëren. 
In dit proefschrift wordt een overzicht gegeven van het pemfigoïd spectrum met de daarbij 
behorende klinische symptomen, het optimale gebruik en interpretatie van diagnostiek zoals 
directe immunofluorescentie (DIF), indirecte immunofluorescentie (IIF) en detectie van antigeen 
specifieke circulerende autoantilichamen in het serum én het toepassen van een “tailor made” 
behandeling bij de pemfigoïd patiënt. 
In 2004 is in ons blaarexpertise centrum te Groningen de serratiepatroon analyse van de
DIF beschreven waarbij een n-serratie of een u-serratie patroon van de immunodeposities langs 
de BMZ kan worden aangetoond. Lineaire deposities vanaf de lamina densa en hoger hebben 
een n-geserreerd patroon, terwijl deposities onder de lamina densa een u-serratie patroon 
vertonen. Het u-serratie patroon ziet men alleen bij de circulerende autoantistoffen tegen coll 
VII, zoals bij EBA of bulleuze systemische lupus erythematosus en het n-serratie patroon bij de 
overige vormen van het pemfigoïd spectrum. Tot op heden wordt er in de dagelijkse praktijk, 
behoudens in ons blaarexpertise centrum, de serratiepatroon analyse van de DIF nog te weinig 
toegepast. De minimale toepassing wereldwijd zou te maken kunnen hebben met onzekerheid 
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in de beoordeling van het serratiepatroon of het ontbreken van expertise en training van derma-
tologen en pathologen. In hoofdstuk 2 wordt een studie beschreven waarin de leerbaarheid van 
de interpretatie van de DIF serratiepatroon analyse wordt getest bij groepen met verschillend 
niveau van expertise in het pemfigoïd spectrum. Een online nversus-test (www.nversus.umcg.nl) 
is ontwikkeld, die 26 DIF afbeeldingen van de BMZ bevat, IgG gekleurd, en gefotografeerd met 
een 40x en 63x vergroting. Alle afbeeldingen zijn van patiënten met een vorm van pemfigoïd. 
Dertien DIF afbeeldingen werden getoond voor een instructievideo en dertien DIF afbeeldingen 
werden getoond na een instructievideo over de beoordeling van DIF serratiepatroon analyse. 
De deelnemers hadden drie keuze opties: n-serratie, u-serratie of niet te bepalen. De test 
werd verricht door drie verschillende groepen deelnemers: i) dermatologen en dermatologen 
in opleiding (i.o.) van het Universitair Medisch Centrum Groningen (UMCG), ii) Internationale 
experts op het gebied van auto-immuun blaarziekten (AIBD), iii) dermatologen en pathologen 
die deelnamen aan de Groninger Blaarcursus tussen 2002-2012. Het aantal correcte antwoorden 
van het serratiepatroon was significant hoger na instructie dan voor de instructie (mediaan 9.0 
correcte antwoorden vs. 11.0 correcte antwoorden, P<.001). Deelnemers aan de test toonden 
een gemiddelde verbetering na instructie van 15.4% in de UMCG groep (66.7% vs. 82.1%), 
16.2% in de Internationale expert groep (67.2% vs. 83.4%) en 12.1% in de Blaarcursus groep 
(60.7% vs. 72.8%). Het u-serratie patroon werd beter herkend dan het n-serratie patroon. 
Onze conclusie was dat DIF serratiepatroon analyse geleerd kan worden onafhankelijk van het 
expertiseniveau van de beoordelaar.
Recent zijn er nieuwe ELISA’s ontwikkeld voor de detectie van autoantistoffen tegen coll VII, die 
kunnen worden toegepast om EBA te diagnosticeren. Er is een commerciële ELISA beschikbaar 
waarbij zowel het NC1 als het NC2 domein op de plaat is gecoat. In de literatuur is van deze 
ELISA een hoge sensitiviteit (>93%) en specificiteit (>96%) beschreven. Tevens is er een cor-
relatie aangetoond tussen de ernst van de EBA bij patiënten en de hoogte van de ELISA index. 
Al deze studies zijn gebaseerd op EBA patiënten met een positieve zoutgespleten humane huid 
(SSS). In hoofdstuk 3 hebben we onderzocht hoe de bijdrage is van de type VII coll ELISA in de 
diagnostiek bij EBA patiënten in de normale dagelijkse praktijk. We verrichten de type VII coll 
ELISA op sera van 28 EBA patiënten uit onze databank: 15 patiënten met een positieve SSS en 
13 patiënten met een negatieve SSS. Serum van gezonde bloeddonoren (n=17) en van patiënten 
met een andere vorm van sAIBD (n=29) dienden ter controle. Bij vier patiënten werd de ELISA 
index gedurende het ziektebeloop gemeten. DIF serratiepatroon analyse werd prospectief uitge-
voerd vanaf 2000 (n=19). De sensitiviteit in de positieve SSS groep was 80%, en in de negatieve 
SSS groep 23%. In de prospectieve EBA populatie toonden we een sensitiviteit van slechts 45% 
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aan. De sensitiviteit van DIF u-serratie patroon analyse was 89%. Tien van deze patiënten waren 
seronegatief bij zowel de ELISA als de SSS, en zouden dus niet als EBA gediagnosticeerd worden 
als alleen serum geanalyseerd zou worden. Van de 46 controle sera, was er één positieve ELISA 
(specificiteit 97.8%). De coll VII ELISA index correleerde met het ziektebeloop bij individuele EBA 
patiënten. Met deze resultaten toonden wij aan dat de coll VII ELISA van weinig toegevoegde 
waarde is in SSS negatieve EBA patiënten. De meerwaarde van de coll VII ELISA is met name dat 
het EBA kan onderscheiden van anti-LN-332 MMP en anti-p200 pemfigoïd patiënten en tevens 
dat het de ziekteactiviteit bij EBA kan monitoren. Echter de DIF u-serratiepatroon analyse blijft 
de gouden standaard bij de diagnostiek voor EBA.
Anti-LN-332 MMP is een zeldzame vorm van pemfigoïd waarbij de IgG autoantilichamen 
gericht zijn tegen LN-332. Klinisch kan anti-LN-332 MMP lijken op andere vormen van pemfi-
goïd. Voor het stellen van de diagnose anti-LN-332 MMP zijn moeilijk verkrijgbare laboratorium 
technieken nodig. Een correcte diagnose is noodzakelijk omdat patiënten met anti-LN-332 MMP 
een relatief verhoogd risico op maligniteiten hebben en daarom ook ten tijde van de diagnose 
oncologisch gescreend moeten worden. In hoofdstuk 4 hebben wij de klinische symptomen en 
immunopathologische bevindingen van tien patiënten uit ons blaarexpertise centrum beschre-
ven. Nieuwe inzichten, zoals benoemd in dit hoofdstuk, hebben geleid tot additionele criteria 
voor de diagnose anti-LN-332 MMP. We hebben een onderverdeling gemaakt in “major” en 
“minor” criteria. Major criteria: 1) Subepidermale erosies of blaren op slijmvliezen met frequent 
verlittekening, 2) IgG immunodeposities langs de BMZ in het n-serratie patroon, 3) IgG in de 
bodem van de blaar bij SSS. Minor criteria: 1) IgG binding aan de α3, β3, of γ2 keten van 
LN-332 bij immunoblot, 2) positieve LN-332 ELISA, 3) Immunoprecipitatie positief voor LN-332, 
4) Negatieve IIF op LN-332 deficiënte huid, terwijl positieve IIF op coll VII deficiënte huid, 5) 
IgG BMZ deposities bedekken LN-332 bij fluorescence overlay antigen mapping (FOAM). Voor 
de diagnose anti-LN-332 MMP moeten er tenminste drie major criteria, of twee major en één 
minor criterium behaald worden. De combinatie van DIF serratiepatroon analyse en SSS zal 
andere vormen van pemfigoïd en EBA uitsluiten van de differentiaal diagnose. 
BP is het meest voorkomende subtype van het pemfigoïd spectrum en wordt vaak bij ouderen 
gediagnosticeerd en is geassocieerd met een significante morbiditeit. In de recent verschenen  
“Definitions and outcome measures for bullous pemphigoid” worden jeuk, urticaria en pral ge-
spannen blaren genoemd als de drie belangrijkste kenmerken van BP. Verwarrend is de subgroep 
patiënten met immunopathologische bevindingen passende bij BP, jeuk en geen ontwikkeling 
van blaren voor jaren. In de literatuur is er geen consensus hoe deze subgroep te definiëren. 
Vooralsnog worden er verschillende definities gebruikt zoals ‘pruritic pemphigoid’, ‘pemphigoid 
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nodularis’, ‘papular pemphigoid’, ‘prurigo-nodularis like pemphigoid’, ‘nonbullous BP’, ‘prodro-
mal BP’, ‘cutaneous pemphigoid’ and ‘BP incipiens’. In hoofdstuk 5 presenteerden wij vijftien pa-
tiënten met immunopathologische bevindingen passende bij BP, met daarbij pruritis sine materia 
of jeukende huidafwijkingen zonder blaren. De diagnose werd gesteld op basis van een positieve 
DIF met IgG en/of C3c langs de BMZ, of SSS epidermale binding van IgG in combinatie met een 
positieve ELISA (NC16A of BP230). De klinische symptomen waren heterogeen en bestonden 
uit: pruritus sine materia (geen primaire efflorescenties), eczemateuze, urticariele, papuleuze 
en/of nodulaire huidafwijkingen. Behandeling met potente topicale corticosteroïden (CS) of 
methotrexaat (5-15 mg/week) gaf complete remissie in elf patiënten. Om de dermatoloog te 
prikkelen om aan pemfigoïd te denken bij ouderen met jeuk stelden wij de allesomvattende 
definitie voor: ‘pruritic nonbullous pemphigoid’. Wij stelden dat wanneer een oudere patiënt 
met therapeutisch refractaire jeuk zich presenteert op de polikliniek, DIF en IIF verricht moeten 
worden om de diagnose ‘pruritic nonbullous pemphigoid’ aan te tonen of uit te sluiten.
Behandeling van BP is een hele uitdaging gezien de oudere leeftijd van de patiënt en de comor-
biditeiten zoals neurologische en cardiovasculaire ziektes die zijn geassocieerd met de leeftijd en 
met BP. De huidige aanbevolen behandeling bestaat uit systemische CS, echter hoge significante 
morbiditeit en mortaliteit is beschreven.
Studies hebben beschreven dat topicale potente CS veiliger zijn dan behandeling met orale CS 
voor BP. In hoofdstuk 6 onderzochten we de effectiviteit en bijwerkingen van de applicatie van 
clobetasol propionate crème van kaak tot teen bij patiënten met milde of ernstige BP. Verder 
analyseerden wij de ochtend urine cortisol spiegel en eosinofiele granulocyten in een aantal 
geselecteerde patiënten. In een retrospectieve analyse van een serie milde (n=40) en ernstige 
(n=34) BP patiënten, werden deze patiënten behandeld met  clobetasol propionate crème (dosis 
20-40g/dag) van kaak tot teen. Patiënten met milde BP bereikten in 90% ziekte controle en in 
ernstige BP in 73.5%. Complete remissie werd in 64.1% (35.9% zonder therapie en 28.2% met 
therapie) bereikt bij milde BP versus 41.2% (5.9% zonder therapie en 35.3% met therapie) bij 
ernstige BP. Lokale bijwerkingen bestonden vooral uit huidatrofie (14.9%) en purpura (5.4%). 
Systemische bijwerkingen waren schaars (n=3) en waren een diep veneuze trombose, hypertri-
chosis en bijnierschorsinsufficiëntie. Systemische effecten van de topicale behandeling met clobe-
tasol propionate crème van kaak tot teen werden geobjectiveerd door daling van de perifere 
eosinofielen, en een daling in het ochtend urine cortisol. Deze resultaten toonden dat clobetasol 
propionate crème van kaak tot teen een effectieve en veilige behandeling is in de inductie fase 
van de behandeling van patiënten met milde en ernstige BP.  Clobetasol propionate crème van 
kaak tot teen wordt beter verdragen dan systemische CS door de patiënt. We adviseren om een 
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immuunsuppresivum toe te voegen als steroïdsparend adjuvans wanneer er een recidief optreedt 
en topicale behandeling niet meer afdoende is.
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